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ABSTRACT 
 
Breast cancer is the most common cancer in women in Western countries. In the early stages of 
development most breast cancers are hormone-dependent, and estrogens, especially estradiol, 
have a pivotal role in their development and progression. One approach to the treatment of 
hormone-dependent breast cancers is to block the formation of the active estrogens by inhibiting 
the action of the steroid metabolising enzymes.  
 
17-Hydroxysteroid dehydrogenase type 1 (17-HSD1) is a key enzyme in the biosynthesis of 
estradiol, the most potent female sex hormone. The 17-HSD1 enzyme catalyses the final step 
and converts estrone into the biologically active estradiol. Blocking 17-HSD1 activity with a 
specific enzyme inhibitor could provide a means to reduce circulating and tumour estradiol 
levels and thus promote tumour regression. In recent years 17-HSD1 has been recognised as an 
important drug target. Some inhibitors of 17-HSD1 have been reported, however, there are no 
inhibitors on the market nor have clinical trials been announced. The majority of known 17-
HSD1 inhibitors are based on steroidal structures, while relatively little has been reported on 
non-steroidal inhibitors. As compared with 17-HSD1 inhibitors based on steroidal structures, 
non-steroidal compounds could have advantages of synthetic accessibility, drug-likeness, 
selectivity and non-estrogenicity.  
 
This study describes the synthesis of large group of novel 17-HSD1 inhibitors based on a non-
steroidal thieno[2,3-d]pyrimidin-4(3H)-one core. An efficient synthesis route was developed for 
the lead compound and subsequently employed in the synthesis of thieno[2,3-d]pyrimidin-4(3H)-
one based molecule library. The biological activities and binding of these inhibitors to 17-
HSD1 and, finally, the quantitative structure–activity relationship (QSAR) model are also 
reported. In this study, several potent and selective 17-HSD1 inhibitors without estrogenic 
activity were identified. This establishment of a novel class of inhibitors is a progressive 
achievement in 17-HSD1 inhibitor development. Furthermore, the 3D-QSAR model, 
constructed on the basis of this study, offers a powerful tool for future 17-HSD1 inhibitor 
development. 
 
As part of the fundamental science underpinning this research, the chemical reactivity of fused 
(di)cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones with electrophilic reagents, i.e. Vilsmeier 
reagent and dimethylformamide dimethylacetal, was investigated. These findings resulted in a 
revision of the reaction mechanism of Vilsmeier haloformylation and further contributed to 
understanding the chemical reactivity of this compound class. This study revealed that the 
reactivity is dependent upon a stereoelectronic effect arising from different ring conformations. 
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INTRODUCTION 
 
Breast cancer is the most common cancer in women in Western Countries. It has been estimated 
that in the United States 178,480 new cases will be diagnosed and 40,460 women will die from 
breast cancer in 2007.
1
 Similarly in Finland, breast cancer is by far the most diagnosed cancer in 
women, with over 3900 new cases reported in the year 2004.
2
 The majority of breast cancers are 
initially hormone-dependent (estrogen receptor positive), and estrogens have a crucial role in 
their development and progression.
3,4
 One approach to the treatment of hormone-dependent 





The biosynthesis of estrogens, the female sex steroids, starts from squalene and proceeds through 
cholesterol and androgens.
6
 17-Hydroxysteroid dehydrogenase type 1 (17-HSD1) is a key 
enzyme in this biosynthetic pathway catalysing the final step (Figure 1) and converting estrone 
(E1) into the biologically active estradiol (E2). Blocking 17-HSD1 activity with a specific 
enzyme inhibitor could provide a means to reduce both circulating and tumour E2 levels and thus 
promote tumour regression. Enzyme inhibitors are molecules that bind to an enzyme and prevent 
a substrate from entering the enzyme's active site or otherwise hinder the enzyme from 
catalysing its reaction. 
 
This thesis describes the synthesis of potent non-steroidal 17-HSD1 inhibitors based on a 
cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-one core. The biological activities and binding of 
these inhibitors to 17-HSD1 and, finally, a quantitative structure–activity relationship (QSAR) 
model are reported. As a part of the study, investigation was made of the chemical reactivity of 
fused (di)cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones with electrophilic reagents, i.e. 
Vilsmeier reagent and dimethylformamide dimethylacetal (DMFDMA). The findings resulted in 
a revision of the reaction mechanism of Vilsmeier haloformylation.  
 
The literature review, which follows below, will focus on known inhibitors of 17-HSD1, with a 
concise discussion of the structure and biological role of the enzyme.  
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1. ENZYME 17-HSD1  
 
17-Hydroxysteroid dehydrogenases (17-HSD) are a group of enzymes responsible for the 
NAD(P)(H) dependent reduction and oxidation reactions of C17 ketosteroids and C17 
hydroxysteroids.
7,8
 As part of the prereceptor control mechanism, they activate and inactivate 
steroid hormones (Figure 1).
9,10
 To date 14 mammalian isoforms have been identified, of which 
at least 11 exist in humans.
11
 The different isoforms of 17-HSD have relatively low sequence 
identity (25-30%) and they differ in catalytic direction, substrate and cofactor specificity, 
subcellular localisation and tissue distribution. The nomenclature of 17-HSD enzymes follows 
the chronological order of description (17-HSD types 1-14).12 17-HSDs are members of the 
short-chain dehydrogenase reductase (SDR) superfamily,
13
 except for 17-HSD5 which is an 
aldo-keto reductase (AKR). 
 
17-HSD from human placenta (17-HSD1, EC.1.1.1.62) was first described in 1958 by Engel 
& Langer who carried out extensive structure–activity experiments with a large and diverse set 
of natural and synthetic steroids.
14,15
 17-HSD1 is a key enzyme in the biosynthesis of female 
sex steroids, catalysing the final step which converts the less potent E1 1 into biologically active 
E2 2 (Figure 1). The reverse inactivating oxidative enzymatic reaction is catalysed by 17-
HSD2.
16
 In physiological environment, 17-HSD1 is mainly a unidirectional reductive enzyme 
utilising NADPH as a cofactor, although in vitro the purified enzyme or cell homogenates can be 
driven to catalyse the oxidative direction.
17,18
 17-HSD1 is also capable of reducing some 
androgens, such as androstenedione 3, into testosterone 4, but only to a minor extent.
18,19
 17-
HSD1 is a widespread enzyme expressed most abundantly in female ovaries, placenta and breast 




1.1 Structure of 17-HSD1 
 
Human 17-HSD1 is active as a soluble cytosolic homodimer.20 Both subunits of the homodimer 
have a molecular mass of 34.9 KDa and 327 amino acid residues.
21
  The 3D X-ray structure of 
native form 17-HSD1 was first presented, at 2.2 Å resolution, in 1995.22 Since then, several 
crystal structures of 17-HSD1 binary and ternary complexes with estrogenic23,24,25 or 
androgenic
26,27,28
 ligands have become available in the Protein Data Bank (PDB).
29
 17-HSD1 
has also been crystallised with two known steroid based inhibitors.
30,31
 In addition, the binding of 
steroids
32,33
 and characteristics of the active site have been studied by molecular modelling.
34,35,36
 
Site-directed mutagenesis experiments have been used to identify the critical residues for the 
enzyme activity and substrate binding.
 37,38,39
 The inactivating isoform 17-HSD2, which     






































Figure 1. The primary enzymes involved in the final steps of E2 biosynthesis. 
 
 
catalyses the oxidation of E2 2 to E1 1 (Figure 1), is bound to the endoplasmic reticulum and its 
3D structure has not been resolved. 
 
The monomeric structure of 17-HSD1 consists of seven parallel -strands, forming a -sheet, 
and eleven -helices (Figure 2a).22,23 The -sheet is surrounded on both sides by three parallel -
helices forming a typical ″Rossmann fold″, which is associated with NAD(P)H binding. The 
structure contains a flexible loop (Ala191 to Glu202) for which crystal structure determinations 
indicate several conformations (for the structures and abbreviations of amino acids see 




 and substrate entry and is 




The ligand binding cavity of 17-HSD1 is a narrow hydrophobic tunnel, hydrophobic atoms 
contributing 72% to the total surface area.
24 
As would be expected, the cavity is complementary 
to substrates resembling hormones both in structure and in volume. As a member of the SDR 
superfamily, 17-HSD1 has the highly conserved and catalytically crucial Tyr-x-x-x-Lys 
sequence and generally conserved Ser in the active site (catalytic triad Tyr155, Lys159 and 
Ser142). E2, the reduced product of the natural substrate E1, binds to the active site via three to 
four putative hydrogen bond interactions, as well as several hydrophobic interactions involving 
the steroid core (Figure 2b).
23 
The hydroxy group at C17 in E2 forms a hydrogen bond to the 
conserved Ser142 and Tyr155 in the catalytic region. At the opposite end of the ligand binding 
cavity, His221 and C3 phenolic hydroxyl form a hydrogen bond,
23
 and also a hydrogen bond to 
Glu282 has been observed.
24 
It has been suggested that steroids are able to move inside  






Figure 2. a) 3D stucture of human 17-HSD1 monomer crystallised with E2 (coloured magenta) and 
NADP
+
 (coloured blue) resolved to 2.2 Å (PDB code 1FDT).
23 
The flexible loop (Ala191 to Glu202) is 
coloured green. b) Orientation of E2 in the ligand binding cavity. The dashed lines indicate plausible 
hydrogen bonding. 
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the active site to some extent,
23
 and superimposition of the available crystal structures has 
revealed variable orientations of several active site residues, indicating some flexibility of the 
enzyme.
40
 C19 steroids, e.g. testosterone 4, can bind to 17-HSD1 in a normal or reverse 
orientation,
27
 and the androgen discrimination is considered to result from the steric hindrance of 




1.2 17-HSD1 and breast cancer  
 
Initially most breast cancers are hormone-dependent, i.e. tumour cells expressing estrogen 
receptors (ER), and estrogens, especially E2, have a pivotal role in their development and 
progression.
3,4
 Breast carcinogenesis evolves over a period of time in a complex process from 
hormone-dependent status into hormone independence. The highest incidence of breast cancer 
occurs in postmenopausal women when ovarian estrogen production has ceased and E2 is 
formed locally in peripheral target tissues, as in the breast. Hormone-dependent breast cancer 
tissue can be considered an endocrine organ since it contains all the enzymes needed for the 
synthesis of E2 from its precursors. 
 
Normal breast tissue expresses the reductive 17-HSD1 and oxidative 17-HSD2 isoforms, the 
type 2 activity being much higher.
41 
The situation is reversed in primary cultures of malignant 
hormone-dependent breast tumours, and 17-HSD1 is expressed in much higher degree.42 
Immunohistochemical studies have suggested that 17-HSD1 plays an important role in the in 
situ regulation of breast tumour E2 production,
43,44,45
 and various breast cancer cell lines have 
been found to express 17HSD1, 17HSD2, or both isoforms.
46
 In addition, the expression of 17-




It is well established that sex steroid metabolising enzymes have an important role in the 
development and progression of breast tumours.
49
 One approach to the treatment of hormone-
dependent breast cancer is to inhibit the action of these enzymes and prevent the formation of the 
sex steroids.
50
 ER positive breast cancer is usually treated with ER antagonists like tamoxifen, 
which by binding to ER prevent E2 induced cell proliferation. Inhibitors of aromatase (CYP19), 
the enzyme primary converting androstenedione 3 into E1 1 (Figure 1), are already used as an 
adjuvant therapy in breast cancer treatment in postmenopausal women,
51,52
 although it has been 
shown that in malignant breast tumours E1 is formed predominantly via E1 sulfatase pathway 
(Figure 1).
53 
E1 sulfatase inhibitors are currently under development.
54 
 Given its crucial role in 
E2 biosynthesis, 17-HSD1 has become an attractive target for inhibitor development for the 
prevention and control of hormone-dependent breast tumour growth. Recently, in vivo efficacy 
of 17-HSD1 inhibition on E2 dependent tumour growth was demonstrated in a mouse model 
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expressing human 17-HSD1.55,56 In addition to breast cancer, endometriosis is another 




1.3 Methods of measuring 17-HSD1 inhibition 
 
Several methods are available for determining 17-HSD1 inhibitory activity. An appropriate 
literature reference for each assay will be given where the inhibition studies are discussed in 
detail.  
 
At present, many primary activity measurements are performed using a human recombinant 
enzyme in a protein based assay or using cell lines (MCF-7, HEK-293) transfected with 17-
HSD1 cDNA. Ovarian granulosa-luteal cells and wild-type ER positive human breast 
adenocarcinoma cell lines MCF-7 and T-47D have also been used. 17-HSD1 is expressed to a 
much higher degree in T-47D cells than in MCF-7 cells.
46,59
 Purified 17-HSD1 from human 
placenta and placental microsome or cytosol preparations were often used before techniques 
employing genetic engineering were readily available. Most of the methods rely on time-
consuming TLC or HPLC separations. Radioactive substrates are commonly used since the 
conversion of labelled E1 into E2 is measured in the presence of potential inhibitors. In order to 
speed up the screening process for 17β-HSD1, homogeneous luminescence resonance energy 
transfer-based immunoassays have been developed utilising europium(III)-chelate-dyed 
nanoparticles.
60,61





The inhibitory potency of a compound is usually expressed as an IC50 value or Ki value or as 
inhibition per cent. Frequently, the mechanism of inhibition is also reported, as reversible or 
irreversible inhibition. The IC50 value is the inhibitor concentration at which half of the enzyme 
activity is inhibited. The Ki value (equilibrium dissociation constant) corresponds to the 
concentration of inhibitor at which the binding site on the enzyme is half occupied. The 
measured values are laboratory and assay dependent and thus comparison of inhibitory potencies 
is challenging. Similar assays can vary in molar proportions of inhibitors and enzyme, and 
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2.    INHIBITORS OF HUMAN 17-HSD1: REVIEW OF THE LITERATURE 
 
Recent years have seen an increase in the number of patents and publications concerning 17-
HSD1 inhibition as pharmaceutical companies have recognised the potential of 17-HSD1 
inhibitor development. Most of the known inhibitors of 17-HSD1 are based on modifications of 
steroidal structures, while relatively little has been published on non-steroidal inhibitors.
62,63
 
Currently there are no 17-HSD1 inhibitors on the market. 
 
An inhibitor of 17-HSD1 should be selective over 17-HSD2 and, most importantly, forego 
estrogenic effects. Antiestrogenic effects or inhibitory activity against aromatase or E1 sulfatase 
can be considered as an extra benefit. A good 17-HSD1 inhibitor should exhibit certain drug-
like properties in order to have sufficient absorption and permeation in biological systems. 
According to the rules of Lipinski,
64
 an orally active compound should not have more than 5 
hydrogen bond donors or 10 hydrogen bond acceptors in its structure. In addition, the molecular 
weight should be under 500 gmol
-1 
and the partition coefficient (log P) less than 5. In general, 
depending on the biological assay, good 17-HSD1 inhibition has been achieved with IC50 
values in (low) nM range or high inhibition% in nM or low M test concentrations.  
 
The review of the literature on inhibitors of human 17-HSD1 is divided into three parts. First, 
the early work on 17-HSD1 inhibition, at the time when the structure of the enzyme was not 
known, will be briefly discussed. Secondly, 17-HSD1 inhibitors based on modifications of 
natural substrates or other steroidal structures will be covered. Finally, small non-steroidal 
molecules useful as 17-HSD1 inhibitors will be reviewed. Figure 3 presents the prevailing 
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2.1 Early work on 17-HSD1 inhibition: 1969-1990 
 
Before the complete amino acid sequence
21
 or the first crystal structure
22 
of 17-HSD1 was 
available, many of the inhibition studies were concentrated on affinity labelling of the enzyme’s 
active site or involved the determination of substrate specificities. Although the significance of 
these early inhibition studies can be debated, some of the results have guided later inhibitor 
development and are thus discussed here. Sections 2.1.1-2.1.3 will describe inhibition studies 
conducted between 1969 and 1990. During this period, 17-HSD1 was considered a 
bidirectional enzyme, and thus most of the inhibition studies were performed under basic 
conditions measuring the oxidative direction of the enzyme. This should be taken into account in 
evaluating these early results. 
 
 
2.1.1 The first inhibition studies 
 
In 1969, ten years after the enzyme was first described, Jabarak & Sack
65
 discovered that the 
oxidative direction of purified soluble placental 17-HSD was competitively inhibited by 
estrogen analogues as well as some non-steroidal compounds. A number of steroids were tested 
against 17-HSD activity, and the most promising inhibitors were 1,3,5(10)-estratrien-3-ol 5 
(17-desoxyestradiol), 17-estradiol 6, 16-difluoroestrone 7 and equine estrogen equilin 8 (Figure 
4). At pH 10.2, these compounds inhibited NAD
+
 dependent oxidation of E2 with IC50 values of 
0.12, 3.7, 2.8, 1.9 M, respectively. Ki values ranged from 0.19 M for 1,3,5(10)-estratrien-3-ol 
up to 4.5 M for 17-estradiol. In addition to the steroidal structures, mitotane (o,p-DDD) 9, 
antiestrogen nafoxidine 10, and diethylstilbestrol 11 (Figure 5) were potent inhibitors of 17-















5 6 7 8
13 14 1612
 
Figure 4. Examples of the first steroidal 17-HSD1 inhibitors. 














Figure 5. The first non-steroidal 17-HSD1 inhibitors. 
 
 
Equilin 8, which is used in present hormone replacement therapy, has been crystallised as 17-
HSD1–equilin–NADP+ complex (PDB code 1EQU), and this more contemporary study showed 
8 at 1 M concentration to inhibit the enzyme activity in transfected HEK-293 cells by 77%.30 
Similar results were recently obtained in T-47D cells (IC50 value 1.7 M), but 8 was also shown 
to lack selectivity and to be an equally potent 17-HSD2 inhibitor.66 
 
In addition to 1,3,5(10)-estratrien-3-ol 5, also other C18 and C19 steroids lacking the oxygen at 
C17 were potent inhibitors of the oxidative direction of soluble placental 17-HSD.67 When E2 
O-3 methyl ether was used as a substrate, 1,3,5(10)-estratrien-3-ol 5, 1,3,5(10),16-estratetraen-3-
ol 12, 3-hydroxy-5,16-andostanediene 13, and 5-androsten-3-ol 14 were the most potent 
inhibitors, with Ki values of 0.04, 0.17, 1.8, and 6.0 M, respectively. For comparison, in this 
study Ki value of 0.4 M was measured for the natural ligand E1. In the same assay, non-
steroidal alcohols were found to be poor inhibitors of 17-HSD, whereas diethylstilbestrol 11 
and the triphenylethylene derivative 15 had Ki values of 0.8 and 2.5 M, respectively.
68
 In 
phosphate buffer the oxidative direction of the purified enzyme was reversibly inhibited by 16-
oxoestrone 16.
69
 The reductive direction was not inhibited, but instead 16 was found to be a 
substrate and was reduced to 16-oxoestradiol more efficiently than E1 to E2.  
 
Unsaturated fatty acids were found to irreversibly inactivate purified placental 17-HSD1 when 
the oxidative direction of 17-HSD1 was investigated.70  Exposure to 200 M of oleic acid or 
arachidonic acid led to complete inactivation in 30 minutes, whereas with linoleic or linolenic 
acid 42-66% of enzymatic activity remained. Saturated C18 stearic acid, methyl and ethyl esters 





, NADH, NADPH), but not steroids like E1, had protective effects against the 
inactivation indicating that fatty acid micelles bind to or near the nucleotide binding sites.  
 
 
                                                                                                                      18
2.1.2 Affinity labelling of the active site 
 
Affinity labels are a class of irreversible inhibitors which covalently bind to the active site 
residues. These inhibitors resemble a particular substrate for the enzyme and are used to identify 










 substituent were found to be 17-HSD1 affinity labels and were used to identify amino 
acid residues in the active site. Progesterone derivatives (21) bearing a bromoacetate 
moiety
79,80,81
 and 12-(bromoacetoxy)-estrene-4-ene-3,17-dione75 22 were also used in the 
affinity labelling experiments (Figure 6).
 
In addition to affinity labels resembling steroidal 















































16-Oxoestrone 16 was found to be a 17-HSD1 affinity label in a borate buffer at pH 8.5.69 
Unlike in phosphate buffer, 16 selectively reacted with arginine residues to form a diol 
intermediate, which subsequently reacted with the borate buffer to give an estratriene–arginine–
borate complex. Also other dicarbonyl compounds (2,3-butanedione, phenylglyoxal), although 
not true affinity labelling agents, photochemically inactivated purified 17-HSD1 in borate 
buffer.
84
 The photooxidation with 2,3-butanedione destroyed all 17-HSD1 Met and Tyr 
residues, and partially His, Leu, Arg and Thr residues. In another study related to identifying 
active site residues, tetranitromethane was shown to modify Tyr residues in 17-HSD1.85  
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2.1.3 Mechanism based 17-HSD1 inactivation 
 
The idea behind mechanism based enzyme inactivation is to create specific substrates that are 
inert until they are within the enzyme's active site. Enzymatic reaction on the substrate generates 
a reactive species which in turn will react with a nucleophilic residue in the active site and form 
a covalent bond yielding irreversible inhibition. Mechanism based inhibitors are often referred to 
as suicide inhibitors. 
 
16-Methyleneestradiol 23 is a good substrate (Km value 8.0 M, pH 9.2) as well as a mechanism 
based inhibitor of purified placental 17-HSD1.86 Enzymatic oxidation in the presence of NAD+ 
produces 16-methyleneestrone 24 (Ki value 261 M, pH 7.0) which is a Michael acceptor and 
reacts in situ with an active site residue and inactivates the enzyme (Figure 7). As a downside, 23 
enhances E2 potency in vivo.
87
 17-[1(R)-1-Hydroxy-2-propynyl]andros-4-en-3-one 25 is a 
rather poor substrate for 17-HSD1, but the oxidised product 17-(1-oxo-2-propynyl)andros-4-






























Figure 7. The concept of mechanism based enzyme activation and the compounds used as 17-HSD1 
suicide inhibitors.  
 
 
In view of the activities of 23 and 25, the E2 analogue 26, lacking the steroid ring D, was 
synthesised in order to create a mechanism based inhibitor with good affinity and reactivity.
89,90 
Under basic conditions 26 had a Km value of 79 M, and was oxidised approximately 400 times 
slower than the natural substrate E2. The oxidised product rapidly inactivated the enzyme 
resulting in the Cys and Lys Michael adducts, which were confirmed in solid state 
13
C NMR 
experiments of the lyophilised enzyme.
91
 Unexpectedly the trifluoromethyl derivative 27 was not 
a mechanism based inactivator but instead an affinity label with Ki values of 59 M and 65 M 
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for the two diastereomers.
92
 It was suggested that the irreversible inhibition by 27 occurred by 




2.2 Steroidal inhibitors of 17-HSD1 
 
Most of the known inhibitors of 17-HSD1 are based on steroid structures, especially the natural 
ligands E1 and E2. The following sections introduce steroidal 17-HSD1 inhibitors, which are 
divided into various subclasses mainly according to the modification site of the steroid core. 
Although the vast majority of these steroidal inhibitors are based on the estra-1,3,5(10)-trien-3-ol 
core, some progestins and E ring modified steroids are included as well. 
 
 
2.2.1 Progestins   
 
Synthetic progestins (Figure 8) have been found to inhibit 17-HSD1 as well as E1 sulfatase 
activity in cell based assays. In intact T-47D cells the C21 steroids nomegestrol acetate 28 and 
antiestrogen medrogestone (Prothil

) 29 had IC50 values of 0.8 M and 0.45 M, respectively, 
making them the best progestin based 17-HSD1 inhibitors reported.93,94 Dydrogestone 
(Duphaston

) 30, which has a 19-methyl group, and its 20-dihydro metabolite 31 are less 
potent, the metabolite being a slightly better inhibitor with an IC50 value of 9 M.
95
 In MCF-7 
cells, which have a much lower 17-HSD1 expression,46 28 and 29 had no or only moderate 
effect on the 17-HSD1 activity.93,94 
 
19-Nortestosterone derivative tibolone 32, the active ingredient in the hormone replacement drug 
Livial

, inhibited 17-HSD1 activity in T-47D cells with an IC50 value of 2.0 M.
96
 Tiboline 
3-OH metabolite 33 was less than half as active as 32, whereas the 3-OH metabolite 34 was a 
better inhibitor with an IC50 value of 1.4 M. The 4-Δ isomer 35 showed only weak inhibitory 
activity (IC50 value 35.3 M). Unlike 28 and 29, tibolone and its metabolites also showed 
inhibition against 17-HSD1 in MCF-7 cells, with IC50 values between 0.79 and 22.8 M.  
 



























28 29 30 31
32 33 34 35
(Org OD14, Livial®)  
 
Figure 8. Synthetic progestins with 17-HSD1 inhibitory activity. 
 
 
The 3D structure of 17-HSD1 complexed with 20-hydroxyprogesterone (20-hydroxy-(20S)-
pregn-4-en-3-one) has been resolved,
97
 although the coordinates for the complex have not been 
published. 20-Hydroxyprogesterone is reported to have a similar binding mode to E2. The 
crystallisation study along with the inhibition studies noted above show that C21 steroids are 
capable of binding to 17-HSD1 and inhibit the enzyme activity.  
 
Although the selectivity of these progestins over 17-HSD2 is not known, 20-
hydroxyprogesterone inhibits the oxidation of testosterone 4 by microsomal 17-HSD.98 On the 
other hand, the inhibitory activity also against E1 sulfatase can be considered beneficial because 
in breast cancer the sulfatase pathway is prominent for E1 formation. Evidently some progestins 
induce 17-HSD1 activity,59,99,100 which could be one reason why these steroids have not been 
employed as lead compounds for 17-HSD1 inhibition. 
 
 
2.2.2 Derivatives of E1 and E2 substituted at C7 or C6 
 
The estrogenic effects of E2 can be prevented by introducing a 7-undecanamide group to the 
steroid core. The E2 derivative 36 (ICI 164384) is a known antiestrogen, which has also been 
shown to weakly inhibit 17-HSD1 and E1 sulfatase activity in rat mammary and  human breast 
tumour tissue (Figure 9).
101
 In a human tumour homogenate, 36 inhibited 17-HSD1 activity 
with a very moderate IC50 value of 0.89 mM. In the same assay, 4-hydroxytamoxifen and 
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desmethyltamoxifen, which are metabolites of the commercial antiestrogen tamoxifen, had a 
minor inhibitory effect against 17-HSD1 with IC50 values up to 2.2 mM. In human placental 
cytosol preparations, 36 at 1 M concentration inhibited 33% of 17-HSD1 activity.102 In a 
mouse uterus assay, derivatives of 36, with an unsaturated ring D or a halogen group at C16, 
acted as potent antiestrogens and 17-HSD1 inhibitors in vivo.103 Whether these derivatives also 







37   X = S
38   X = O























Figure 9. Derivatives of E2 and E1 substituted at C6 or C7. 
 
 
The inhibitory activity was improved by moving the N-butyl-N-methyl alkyl amide side chain to 
the C6 position of E2 (Figure 9). The 6-thiaheptanamide derivative 37 had an optimised side 
chain length of five methylenes and was able to reversibly inhibit 17-HSD1 in human placental 
cytosol preparations with an IC50 value of 0.17 M.
102
 Compound 37 showed almost identical 
activity in 17-HSD1 transfected HEK-293 cell homogenates.104 The C6 -configuration, C3 
hydroxy group and the side chain amide moiety (-CONBuMe) were shown to be important 
structural features, as the removal of each significantly reduced the activity. Replacement of the 
6-thioether bond with a chemically more stable ether or carbon–carbon bond also reduced the 
activity, as was shown with compounds 38 (IC50 value of 0.8 M) and 39.
105
 In intact HEK-293 
cells the inhibitory activity of 37 and 39 was reduced to approximately half, whereas in intact T-
47D cells, which better represent physiological conditions, the activity was much higher, likely 
due to lower 17-HSD1 expression. In the T-47D cells, 37 and 39 were equally potent, with 82% 
17-HSD1 inhibition at 1 M. The C2 methoxy and E1 derivatives 40 and 41 were less potent, 
with 32% and 57% inhibition at 1 M concentration, respectively.105  
 
Compounds 37 and 39-41 are reported to show some selectivity over the reductive isoforms 17-
HSD7 and 17-HSD12,105 and 37 was also selective over 17-HSD2 and 17-HSD3.102 
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Although structurally related to the antiestrogen 36, at 0.01 M concentration 37 exhibited 
strong estrogenic effect in T-47D and MCF-7 cell lines.
104,105 
For 38 the proliferative effect in T-
47D cells was only seen at higher concentrations (0.1 M and 1.0 M), and also 39 was less 
estrogenic than the 6-thiaheptanamide derivative 36. As postulated, the C2 methoxy derivative 










have developed a series of C16 substituted E2 derivatives 
designed to be irreversible inhibitors of 17-HSD1. Affinity labelling experiments had already 
shown that inhibition of 17-HSD1 could be achieved by an electrophilic substitution on E2 ring 
D.
72,75
 16-Propyl derivatives of E2 such as compounds 42a-42e, with a good leaving group at 
the end of the alkyl chain, were found to competitively and irreversibly inhibit partially purified 
placental 17-HSD1 (Figure 10).106 16-(3’-Iodopropyl)estradiol 42d and 16-(3’-
bromopropyl)estradiol 42c were the most potent inhibitors, with IC50 values of 0.42 and 0.46 
M, respectively. Similar activity was obtained with the E1 derivative 16-(3’-
bromopropyl)estrone 43 (IC50 value 0.31 M).
107
 Introduction of the side chain to the 17-
position of E2, variation of the C16 configuration or variation of the side chain length reduced 
the activity.
108
 In fact, the 16-derivatives with a brominated ethyl or propyl chain were 
chemically unstable and readily underwent cyclisation. In addition to the partially purified 
enzyme, 16-(3’-bromopropyl)estradiol 42c at 100 nM concentration inhibited approximately 
88% of the 17-HSD1 activity in transfected HEK-293 cells, exhibiting selectivity over 17-
HSD type 2, type 3 and type 5.
18
 Unfortunately, the E2 derivatives, such as 42c are estrogenic 
and stimulate the growth of ZR-75-1 breast cancer cells.
 109 
 
In a subsequent study,
110
 a C16 bromobutyl side chain was attached to the known antiestrogen 
and 17-HSD1 inhibitor ICI 164384 36 (see section 2.2.2) with a view to producing a dual 
action inhibitor with an additional antiestrogenic effect. This strategy led to decreased inhibitory 
potency compared with 36, although satisfactory antiestrogenic properties were retained. Better 
results were obtained when the N-methyl-N-butyl alkylamide moiety present in 36 was 
introduced to the C3’ position of 16-(3’-bromopropyl)estradiol 42c to give compound 44a 
(Figure 10).
111
 For this dual biological action, the optimal length of the methylene linker between 
the C3’ and the amide moiety was determined to be five carbons (compound 44b).109 















42a  X =  F
42b  X =  Cl
42c  X =  Br
42d  X =  I












Figure 10. Derivatives of E2, bearing a halogenated C16 alkyl or C16 alkylamide side chain. 
 
 
When measured on partially purified 17-HSD1, 44b had a moderate IC50 value of 10.4 M, but 
on the other hand it had no estrogenic activity up to 0.03 M concentration, and at 1 M 
concentration it also exhibited 74% antiestrogenic effect.
109
 Removal of the amide moiety from 
the side chain increased the inhibitory potency but restored the estrogenic activity. The enzyme 
activity was unexpectedly restored after incubation of 17-HSD1 with NADH and 44, indicating 
reversible inhibition. Replacement of bromine at C3’ with a bromomethylene group gave the 





The described approach to create dual action 17-HSD1 inhibitors failed to produce compounds 
with high affinity to the enzyme. Nevertheless these studies importantly showed that 17-HSD1 
inhibition can be achieved with steroids bearing relatively large substitutents at the C16 position. 
 
 
2.2.4 Derivatives of E1 and E2 substituted at C16   
 




who have developed a large and versatile library of C16 substituted E1 and E2 derivatives 
bearing additional substituents at C2, C6 or O-3 positions. Poirier and co-workers had already 
established that large substituents at C16 of E2 are tolerated,
109,111
 and molecular modelling 
studies suggested space for significant expansion from the C16 position of E1 resulting in 
possible interactions with the cofactor. The addition of substituents of various size to the C16 
position was conducted in stepwise manner. First, a series of compounds 46, 47 and 48 with 
small hydrophobic alkenyl and alkyl moieties was synthesised and their biological activity 
evaluated (Table 1).
113
 The C16 alkenyl derivatives of E1 46a-46h can be synthesised from E1  
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Table 1. Selected examples of C16 alkenyl E1 and E2, and 16-alkyl E2 derivatives, and their biological 
activity.
113,116
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 17-HSD inhibition% at 10 M113 Purified 17-HSD1116 





Type 1 Type 2 Type 1 Type 2 IC50 (M) IC50 (M) IC50 (M) 
a 82 31 84 27      
b 17 <10 26 <10   10-32 3.4-5.6 0.8-1.0 
c 34 25 77
c
 <10 84 37    
d 23 16 55 17 88 11 >20 9.3-12.6 2.4-5.5 
e 44 10 52 43 87 11 8.6-18 7.5-16 3.3-4.2 
f 72 13 72 81 41 25 >40 7.0-14 4.0-5.7 
g       1.1-3.4   
h       3.8-4.0   
i     86 17   
 




[a] In T47-D cells. [b] In MDA-MB-231 cells. [c] IC50=4.1 M. [d] Compound 24. [e] Compound 23. 
 
 
via straightforward aldol condensation with an appropriate aldehyde. Subsequent NaBH4 
reduction of the C17 carbonyl moiety followed by hydrogenation of the double bond gives the 




Some of the compounds 46-48 showed auspicious activity against 17-HSD1 in T-47D cells and 
selectivity over 17-HSD2 (Table 1).113 The generally improved activity with the 16-alkyl 
derivatives 48a-48f indicated that flexibility of the C16 side chain allows more propitious 
orientation of substituents. The most potent inhibitors in this series were 6-
(ethoxymethyl)estrone 49 (IC50 value 0.32 M) and 16-dimethylestrone with 92% and 95% 17-
HSD1 inhibition at 10 M concentration, respectively.113,117 Also compounds containing a 
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pyridyl moiety in the side chain showed promising inhibition. In general, similar results to those 
obtained in the cell based assay were obtained by Poirier et al.,
116
 who evaluated compounds of 
type 46-48 against purified human 17-HSD1 (Table 1). The best inhibitor of the purified 
enzyme was found to be the 16-benzyl substituted E1 derivative 48b with an IC50 value of 0.8–
1.0 M.  Docking of 48b into the active site of 17-HSD1–E2 complex (PDB code 1IOL) did 
not reveal any significant interactions between the benzyl moiety at C16 and the catalytic triad, 
but the E2 core was slightly shifted enabling the phenyl group to approach the hydrophobic 
region formed by Leu96 and Val196.
116 
Whether the 17-HSD1 inhibition with compounds 46a-
46i is reversible or irreversible has not been investigated. 16-Methyleneestrone 24, which Poirier 
et al.
 
used as a lead and reference compound, nevertheless, is a known 17-HSD1 alkylating 
agent.
86
 It is not likely that series 47 and 48 are irreversible inhibitors as they lack a suitable 




 continued to explore the C16 substitution by incorporating carboxyl or 
methyl carboxyl side chains to E1 and E2 (compounds 50-52, Figure 11, Table 2). These 
compounds can be synthesised by alkylating O-3 protected E1, e.g. by using LDA and 
bromoethylacetate, which produces the ethyl estrone-16-acetate 51b. Compounds bearing amide 
sidechains were synthesised from the carboxylic acid derivatives 50a and 51b by standard amine 
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Figure 11. Selected examples of C16 carboxyl and C16 methylene carboxyl derivatives of E1 and E2 
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Table 2. Selected examples of C16 alkenyl E1 and E2, and 16-alkyl E2 derivatives, and their biological 
activity.
113,115
 Dashed lines indicate the point of attachment. 
  Inhibition% at 10 M Inhibition% at 1 M IC50 (M) 
  17-HSD1a 17-HSD2b 17-HSD1 17-HSD1 




51 53 54 
a   OH 39 13 58 <10      
b O   97 67 18   0.30   
c NH  
 90 63 <10   1.5   
d NH  
 84 76 <10 ni
d 
























          *R 1.31 































 58  14      
[a] Measured in T-47D human breast cancer cells. [b] Measured in MDA-MB-231 human breast cancer 
cells. [c] 3:1 (/) Mixture of diastereomers. [d] No inhibition. 
 
 
In the C16 carboxyl series 50a-50k, the E2 derivatives bearing an amide moiety in the side chain 
showed promising inhibition and excellent selectivity to 17-HSD1 over 17-HSD2 (Table 2). 
In T-47D cells the 17-HSD1 inhibition ranged between 70% and 91% when measured at 10 M 
concentration as a mixture of diastereomers. The C16 methylene carboxyl derivatives 51a-51m 
of E1 were generally equally or more potent than the corresponding E2 carboxyl derivatives 50a-
50k. The m-pyridyl derivative 51k, as a 2:1 mixture of diastereomers, was discovered to be a 
strong and selective inhibitor of 17-HSD1 with a low IC50 value of 37 nM.
114
 The major isomer 
16 of 51k was isolated and found to have the same inhibitor potency.113 The corresponding E2 
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derivatives 52a-52f showed reduced activity indicating that the E1 core is preferred. However, 




 to reducing the possible estrogenic effects of the potent inhibitor 51k, synthesis of 
the corresponding C2 methoxy and C2 ethyl derivatives 55 and 53k (Figure 12) was 
undertaken.
114
 Estrogen derivatives bearing substituents at C2 position have reduced estrogenic 
activity, and in silico studies have suggested that substitution at C2 disrupts key hydrophobic 
interactions between E1 and the binding site of ER. The 2-methoxy derivative 55 (mixture of 
diastereomers) showed one–eight the inhibitory activity of 51k, whereas the enantiopure 16 2-
ethyl derivative 53k exhibited enhanced activity with an excellent IC50 value of 27 nM (Figure 
12).
114
 The substitution at C2 also improved selectivity between the isoforms, and 53k did not 
show any inhibition of 17-HSD2. When the ethyl moiety was introduced to the other C16 
acetamide derivatives, an additive effect on biological activity was only observed with the o-
pyridyl derivatives 53l (Table 2).
115
 Surprisingly, the C2 ethyl derivatives bearing an aliphatic 









51k    R = H    IC50  37 nM







55  IC50  290 nM
 
 
Figure 12. The effect of substitution at C2 position on 17-HSD1 inhibition.114 
 
 
The addition of a 3-O-sulfamoyl to 53k significantly reduced the inhibitory activity, compound 
54k having an IC50 value of 5.1 M.
115
 It was postulated that the sulfamate group could act as a 
larger hydrogen bond acceptor/donor moiety, or possibly as a prodrug for the free phenol at C3 
position. In addition, the 3-O-sulfamate E1 based inhibitors (54) could reversibly bind to 
carbonic anhydrase II enzyme in red blood cells and in this way be transported to tumours.
118
 In 
general, the 3-O-sulfamate series 54 (Figure 11, Table 2) exhibited only weak or moderate 
activity suggesting loss of a hydrogen bond interaction, e.g. with His221 and Glu282, or loss of 
hydrophobic interactions to the ethyl group at C2. It should be noted that except for 53k, which 
was a pure 16-isomer, the C2 ethyl libraries 53 and 54 were approximately a 3:1 mixture of / 
diastereomers. The phenol and sulfamate libraries 53 and 54 were synthesised from 2-





                                                                                                                      29
Docking of the best two inhibitors, 51k and 53k, into the active site of 17-HSD1–E2–NADP+ 
complex (PDB code 1FDT) suggested a binding mode where the steroid core of the inhibitor was 
closely overlaid with E2.
113 
The side chain pyridyl m-nitrogen in 51k and 53k was close to the 
phosphate oxygen of NADP
+
. The proximity of the side chain C16 methylene with the cofactor 
pro(S) hydrogen could cause interference with the hydrogen transfer to the C17 carbonyl and 
prevent these inhibitors from acting as substrates. Compound 53k exhibited additional 
hydrophobic interaction involving the ethyl group at C2, which could have contributed to the 
slightly better inhibitory activity than for the desethyl analogue 51k. The inhibitory data for few 
selected compounds without a substituent at C2 or O-3 position was utilised to create a QSAR 
model with reasonable predictive power.
113
 This study is one of only two small QSAR studies 
with 17-HSD1 reported so far.113,117 
 
These extensive studies by Potter and co-workers have confirmed that good inhibitory activity 
and selectivity can be obtained by introducing a large and flexible side chain to the C16 position 
of E1. The inhibition measurements were performed using T-47D breast cancer cells which 
represent the physiological situation and show that these types of inhibitors are able to pass 
through the cell membrane. Although the C2 substituted derivatives were synthesised with a 
view to reducing the possible estrogenicity of these inhibitors, actual data regarding estrogenic 
effects were not reported. 2-Ethyl-3-hydroxy-17-oxo-N-(3-pyridinylmethyl)-(16)-estra-
1,3,5(10)-triene-16-acetamide 53k
114
 (IC50 value 27 nM) is one of the most potent 17-HSD1 
inhibitors reported to date and has the lowest IC50 value obtained with a cell based assay. 
 
 
2.2.5 Derivatives of E1 and 1,3,5(10)-estratrien-3-ol substituted at C15 
 
Continuing to explore substitution on the D ring of E1, Solvay Pharmaceuticals has patented C15 
substituted E1 and O-3 methyl E1 derivatives as 17-HSD1 inhibitors.119 This group of 
inhibitors includes compounds with an amide, sulfonamide, urea, carbamate or hydroxyl side 
chain connected via an alkyl linker to the C15 position of E1 or 3-methoxyestrone. In a further 
patent, more inhibitors bearing C15 amide side chains were reported with additional substituents 
at C2 and modifications of the steroid core.
120
 In general, these C15 substituted E1 derivatives 
were synthesised in steps from the O-3 protected 15,16-unsaturated estrones. Michael addition of 
different nucleophiles bearing, for example, an ester or nitrile moiety, produced C15 side chains 
that could be further fuctionalised. 
 
Representative inhibitor structures 56-65 and their rec17-HSD1 inhibitory activity in a protein 
based assay are shown in Table 3. The most potent of these inhibitors was N-cyclooctyl-3-
methoxy-17-oxo-estra-1,3,5(10)-triene-15-propanamide 56a, producing 85% and 95% 17- 
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Table 3. Selected examples of C15 substituted E1 and estrien derivatives patented by Solvay 







O56a  n = 1 
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57a  R1=H,  R2 =H
57b  R1=H,  R2=Me
57c  R1=Bu, R2 =H
57d  R1=H,   R2=SO3H







































Inhibition% of rec17-HSD1 
 100 nM 1 M  100 nM 1 M  100 nM 1 M 
56a 85 95 57e 10 43 62 80 95 
56b 42 85 58a 80 87 63 63 93 
57a 50 80 58b 60 92 64a 64 82 
57b 25 75 59 49 91 64b 32 85 
57c 38 79 60 76 97 65 71 91 
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HSD1 inhibition at 100 nM and 1 M concentration, respectively.119 These results demonstrate 
that a hydroxy group at C3 of the steroid core is not essential for the binding of these inhibitors. 
Besides the amide side chain (e.g. in 56a and 57a), also the other side chain types, bearing alkyl, 
aromatic or heterocyclic moieties, were potent inhibitors, the differences in biological activity 
being more apparent at the lower, 100 nM test concentration. In general, 15-configuration 
seemed to be favoured, with the exception of the sulfoamides (e.g. compound 62), where only 
the 15 substitution was reported. Compound 57a bearing a 4-(4-morpholinyl)-4-oxobutyl side 
chain at the C15 -position inhibited rec17-HSD1 activity 50% at 100 nM concentration. The 
efficacy of compound 57a was additionally demonstrated in vivo in a nude mouse model.
55
 
Inoculation of the nude mice with MCF-7 tumour cells expressing human 17-HSD1 led to the 
growth of hormone-dependent tumours. Four-week subcutaneous administration of 57a (5 
M/kg/day) resulted in 60% reduction in tumour size as compared with the non-treated controls.  
 
Introduction of an additional n-butyl or a methoxy or an ethoxy group to the C2 position of these 
E1 derivatives appeared to reduce the inhibitory activity slightly.
120
 Replacement of the C3 
hydroxy or methoxy group in 57c with a sulfate or sulfamate moiety was not tolerated and the 
inhibitory activity was lost (compounds 57d and 57e). On the other hand, increased activity was 
obtained with compounds  63, 64a and 65 in which the E2 core was changed to 2'H-estra-
1,3,5(10),16-tetraeno[17,16-c]pyrazol-3-ol 66 or to17,17-difluoro-estra-1,3,5(10)-trien-3-ol 78. 
These compounds are known to be potent 17-HSD1 inhibitors (see below). 
 
Compounds of type 56-65 were patented by Solvay as selective and non-estrogenic or 
antiestrogenic 17-HSD1 inhibitors. However, actual experimental data regarding the selectivity 
or estrogenic effects of these compounds has not been reported, except for compound 57a which 









 discovered that heterocyclic analogues of E1 with a pyrazole or an isoxazole 
fused to 16,17-position on ring D were competitive inhibitors of purified placental 17-HSD1. 
Estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ol 66 (Figure 13) was the best inhibitor, with a Ki value 
of 4.08 M when the oxidation of E2 was measured. The corresponding isoxazole derivative was 
only one-seventeenth as potent. Methylation of the hydroxy group at C3 position caused a 3- to 
6-fold decrease in the affinity of the compounds, including E1. 
 
 









67  R = H    68  R = CF3
69  R = CO2Et
n
66  n =1, X=N
 
 





 utilised the pyrazole 66 and 16-(hydroxymethylene)estrone 67 as lead 
compounds to develop a series of N1’, N2’ or 5C’ substituted estra-1,3,5(10)-trieno[17,16-
c]pyrazoles as 17-HSD1 inhibitors (Figure 13, Table 4). In T-47D cells 16-
(hydroxymethylene)estrone 67 (IC50 value 0.11 M) and its alkylated derivatives 68 and 69 
showed good selectivity and promising inhibition of 17-HSD1. In view of the plausible 
intramolecular hydrogen bonding, they were postulated to be bioisosteres of a fused steroidal 
ring E (Figure 13). Similarly, 16-oximeestrone was a good and selective inhibitor with an IC50 
value of 1.1 M. In this cell based assay the pyrazole 66, as a mixture of 1’-H and 2’-H 
tautomers, had an IC50 value of 0.18 M and at 10 M concentration was able to inhibit 97% of 





analogues were slightly less potent, with 86% and 78% inhibition, respectively. Reduced activity 




The N1’ alkylated estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ols 70a-70e at 10 M concentration 
proved to be good inhibitors of 17-HSD1 in T-47D cells, the inhibition ranging from 77% to 
95%.
117
  In general these compounds exhibited only moderate selectivity over 17-HSD2 (Table 
4). For example, the N-methoxyethyl derivative 70d had an IC50 value of 0.53 M but lacked 
sufficient selectivity over 17-HSD2. The corresponding N2’ alkylated derivatives 71a-71d 
were slightly less potent 17-HSD1 inhibitors. C5’ alkylation of estra-1,3,5(10)-trieno[17,16-
c]pyrazol-3-ols produced the ethyl ester 72a and hydroxymethyl 72b derivatives with IC50 values 
of 1.85 M and 0.95 M, respectively.117 Unlike the N-alkylated derivatives, 72a and 72b 
displayed excellent selectivity over 17-HSD2. In a luciferase reporter gene assay, 66 was 
shown to be estrogenic already at 100 pM concentration, whereas the N-methoxyethyl derivative 
70d did not show any estrogenic activity up to 100 nM concentration, and in silico evaluation of 
70d indicated that it is unlikely to bind to ER.117 The pyrazole derivatives 70-71 can be 
synthesised as a separable mixture by alkylation of O-3-Bn protected 66 with NaH and an 
alkylhalide, whereas 66 and 72a-72d are synthesised starting from the corresponding 16-
(hydroxymethylene)estrones in a cyclisation reaction with NH2NH2.
117 
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  Inhibition % at 10 M IC50 (M)  Inhibition % at 10 M 
  17-HSD  17-HSD 




Type 1     Type 1 Type 2 
H 66
c 
   97 32 0.18    
CH3 70a    94 24 2.75   71a 43 32 
CH2CH(CH3)2 70b    77 61    71b 70 44 
CH2CO2CH3 70c    95 19 0.92   71c 79 30 
(CH2)2OCH3 70d    95 48 0.53   71d 83 55 
(CH2)2CN 70e    95 44 0.73      
CO2Et 72a    94 7 1.85    
CH2OH 72b    94 -1 0.95    
COOH 72c    32 -6     
CF3 72d    75 36     
[a] Measured in T-47D human breast cancer cell line. [b] Measured in MDA-MB-231 human breast 
cancer cell line. [c] A mixture of 1’-H and 2’-H tautomers. 
 
 
Previous studies with C16 substituted E1 derivatives had indicated beneficial interactions 
between amide side chain and the cofactor (see section 2.2.4).
113 
This approach also proved 
successful in the C5’ substituted compounds 74a-74g (Table 5).117,122 3-Hydroxy-N-[2-(3-
pyridinyl)ethyl]-1'H-estra-1,3,5(10)-trieno-[17,16-c]-pyrazole-5'-carboxamide 74f was found to 
be highly selective and the most potent C5’ substituted inhibitor, with an IC50 value of 0.30 M. 
Also other compounds containing a pyridyl moiety in the C5’ side chain were found to be potent 
17-HSD1 inhibitors. However, primary aliphatic amides showed only moderate inhibitory 
activity. Addition of an ethyl group to C2 position of the steroid core, an approach which also 
previously has been propitious, led to decreased activity, as did the addition of O-3-sulfamoyl 
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Table 5. Selected examples of estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ols bearing a C5’ amide side 
chain, and their biological activity.
115,117  























  Inhibition% at 10 M IC50 Inhibition% at 1 M IC50 
  74 74 74 75 76 76 
      R 17-HSD1a 17-HSD2b M 17-HSD1 M 
a N
 







































   15 68  
[a] Measured in T-47D human breast cancer cell line. [b] Measured in MDA-MB-231 human breast 
cancer cell line. [c] No inhibition. 
 
 
The binding modes of the N1’ methoxyethyl derivative 70d, the most potent C5’ amide 74f and 
its C2 ethyl analogue 76f have been investigated by docking the structures into the active site of 
17-HSD1–E2–NADP+ ternary complex (PDB code 1FTD).115,117 The steroid cores of 70d and 
74f in the ligand binding cavity were overlaid and they formed the same hydrophobic 
interactions as E2. For both compounds, a possible favourable electrostatic interaction was 
suggested between the hydrogen bond acceptor in the side chain (ether oxygen or amide 
carbonyl) and the primary amide in NAPD
+
. In 76f the ethyl group at C2 was in a hydrophobic 
region and the hydroxy group at C3 was hydrogen bonded with His221, as in E2. In the best 
binding mode for 76f the pyrazole ring nitrogens were 1.9-2.1 Å from the NADP
+
 pro(S) 
hydrogen, and the C5’ amide carbonyl was in close proximity (3 Å) to the amide moiety in 
NADP
+
 possibly forming - interactions. The m-pyridyl moiety extended to the phosphate 
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region of NADP
+
, which could further aid the binding. Compound 76f was also docked into the 
ligand binding cavity of ER (PDB code 3ERD), where a poor fit was observed indicating that 
this compound is probably not strongly estrogenic.
 
In addition to the docking studies, 
comparative molecular field analysis (CoMFA) was used for few C5’ substituted pyrazole 





2.2.7 Fluorinated derivatives of 1,3,5(10)-estratrien-3-ol and gona-1,3,5(10)-trien-3-ol 
 
The drug discovery efforts described above were mainly concentrated on introducing rather large 
and flexible substituents to the estrien ring D or to the heterocyclic ring E. The early work with 
steroidal 17-HSD1 inhibitors had already established that relatively good inhibitory activity can 




 recognised that 
good 17-HSD1 inhibition can be obtained with fluorine substituted estriens. In theory, the polar 
non-hydrolysable fluorine groups at C17 imitate the transition state of the enzymatic reaction; 
fluorine, as a hydrogen bond acceptor, potentially mimics the carbonyl or hydroxyl group. 
 
Fluorinated 1,3,5(10)-estratrien-3-ols 77-80 and gona-1,3,5(10)-trien-3-ols 81-82 were shown to 
inhibit various isoforms of 17-HSD.123 In this compound class (Figure 14), 7,17,17-trifluoro-
(7)-estra-1,3,5(10)-trien-3-ol 77 was the most potent inhibitor of human rec17-HSD1 with 
74% inhibition at 2 M concentration. Compound 78, which lacks the 7-fluorine, showed 
slightly reduced activity. An introduction of a C2 methoxy or C2 ethoxy substituent to 78 further 
decreased the activity, and addition of a 16-hydroxy group led to complete loss of the activity. 
Most of these fluorinated steroids were unselective 17-HSD1 and 17-HSD2 inhibitors, 77 
showing some selectivity towards the type 1 enzyme. The C18 methyl group in gona-1,3,5(10)-











78 R=H    61% (62%)
81 R=Me  68% (81%)
79 R=H    67% (70%)
82 R=Me  61% (91%)




80  61% (85%)
 
 
Figure 14. Examples of the most potent fluorinated estrien derivatives and their 17-HSD1 inhibition% 
at 2 M. The inhibition% of the oxidative 17-HSD2 is given in parenthesis.123 
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As postulated, docking of 77 to the 17-HSD1–E2–NADP+ complex (PDB code 1FTD) 
suggested a hydrogen bond between the 17-fluorine and the catalytic residues Ser142 and 
Tyr155.
123
 This docking study also suggested that the 7-fluorine occupies an additional cavity 
formed by Pro187, Val225 and Phe226, which could explain the slightly better activity and 
selectivity of this compound as compared with 78.
 
 
Although most of these fluorinated derivatives showed promising inhibitory activity, the lack of 
selectivity between the isoforms can be considered as a major disadvantage. Also, the possible 
estrogenic effects of the derivatives are not clear. Nevertheless these structures are good lead 
compounds for further inhibitor development. 
 
 
2.2.8 C2 substituted estra-1,3,5(10)-trien-3-ols and D-homo-estra-1,3,5(10)-trien-3-ols 
 
Most of the investigations described so far have targeted the steroidal D ring as the modification 
site for producing 17-HSD1 inhibition. Additional substituents were introduced to the C2 
position of the estrien core to increase selectivity and reduce possible estrogenic effects. Just 
recently, very good 17-HSD1 inhibition was obtained by introducing small substituents to the 
C2 position of E1 (Figure 15).
124
 The estrogen metabolite 2-methoxyestrone (IC50 value 2.4 M) 
and 2-ethylestrone 83 at 10 M concentration inhibited 17-HSD1 activity 91-96% in T-47D 
cells.
66
 The inhibition by 2-methoxyestrone was unselective, as 87% inhibition of 17-HSD2 




together with Schering AG have patented a series of 2-substituted 
estra-1,3,5(10)-trienes 83-89 and D-homo-estra-1,3,5(10)-trienes
 
90-95 as selective 17-HSD1 
inhibitors (Figure 15). In a human rec17-HSD1 based assay, 2-chloroestrone 84a showed 
promising activity with an IC50 value of 140 nM. The activity of 84a was increased with an 
addition of C18 methyl or C16 fluorine group, and 2-chloro-16-fluoroestrone 85 with an IC50 
value of 35 nM was the most potent inhibitor reported among the E2 derivatives.
124
 Compounds 
83, 88 and 89 also showed good inhibitory activity, indicating that bulky substituents at C2 
position are well tolerated. Replacing the E2 core with a D-homoestrone core resulted in increase 
of activity (compounds 90-95).
125
 The best inhibitors were 2-(2-phenylethyl)-17a-oxo-17a-
homoestra-1,3,5(10)-trien-3-ol 95 and 2-allyl-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 94 
with IC50 values of 15 nM and 24 nM, respectively. This makes them the most potent steroidal 
17-HSD1 inhibitors reported to date. The D-homo-estra-1,3,5(10)-trienes 90a-90c bearing a 
halogen in the C2 position were also very potent inhibitors. Unlike in the E2 series an 
introduction of 17-fluorine, as in 92, slightly decreased the activity, and 17-fluorine derivative 
91 was even less potent. Also 2-methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 93 showed  









84a  R = H     IC50 140 nM







88  IC50  56 nM
HO
O
89  IC50  47 nM
HO
O







IC50 = 15 nM
HO
O




90a  X = Br  IC50 = 52 nM
90b  X= I     IC50 = 52 nM
90c  X = Cl  IC50 = 77 nM
















86 IC50 = 101 nM
 
 
Figure 15. Examples of C2 substituted estra-1,3,5(10)-trien-3-ols and D-homo-estra-1,3,5(10)-trien-3-ols 
and their biological activity in rec17-HSD1 based assay.124,125 
 
 
good activity, with an IC50 value of 85 nM. For comparison, an IC50 value of 109 nM was 
measured for the substrate E1. 
 
Neither estrogenicity nor selectivity data was reported for these E1 and D-homoestrone 
derivatives. The C2 substitution is likely to prevent or reduce estrogenic effects. However, 2-
methoxyestrone has been shown to be an equally potent 17-HSD2 inhibitor,66 and one may 
suspect that the other compounds bearing solely a small substituent at C2 are unlikely to be 
selective. Nevertheless this approach elegantly confirms that strong 17-HSD1 inhibition can be 
achieved with only subtle changes in the steroid core. 
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 were the first to propose substrate–cofactor hybrid compounds as 17-
HSD1 inhibitors, i.e. inhibitors interacting with both cofactor and steroid binding sites. Their 
hypothesis was that an ideal hybrid inhibitor should possess a complementary hydrophobic 
moiety, such as E2, to interact with the ligand binding domain of 17-HSD1, and an additional 
polar moiety to interact with the hydrophilic cofactor binding site (Figure 16).  This approach 
was first explored with compounds of type 96 where E2 was linked to a natural amino acid via a 
16-aminopropyl spacer. Although these amino acid derivatives of E2 failed to inhibit 17-
HSD1 activity, affinities towards steroid receptors were not detected either. In a subsequent 
study,
127
 analogues of 96 bearing a R
2
 methyl group and R
1
 benzyl group, were shown to be 



























Further elucidation of the concept of dual-site inhibition by means of molecular modelling 
suggested E2-adenosine hybrid compounds as potential inhibitors.
31
 These E2-adenosine 
hybrids
128
 were found to be strong reversible competitive inhibitors of 17-HSD1 in transfected 
HEK-293 cells.
129 
EM-1745 97 had an IC50 value of 52 nM and a Ki value of 3.0 nM, and was 
found to have a methylene linker of optimal length (8 carbons) between E2 and the adenosine 
moiety (Figure 17). In addition, the 16-configuration was shown to be preferred. Neither 5-
nonaoyl-O-adenosine nor 16-nonylestradiol was an inhibitor, demonstrating the importance of 
both the E2 and adenosine moieties in 97. Poor results were also obtained when adenosine was 
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The binding mode of the hybrid inhibitor 97 was confirmed by resolving the X-ray crystal 
structure of 17-HSD1–EM-1745 complex to 1.6 Å.31 Up to 40 Van der Waals contacts and 
several plausible hydrogen bond interactions were found between 97 and the substrate and the 
cofactor binding sites (Figure 17). Superimposition of complexes 17-HSD1–EM-1745 (PDB 
code 1I5R) and 17-HSD1–E2–NADP+ (PDB code 1FTD) revealed identical positioning of the 



























    mimic
98a  R = CO2Me
98b  R = COOH





Figure 17. Hybrid inhibitor EM-1745 and the plausible hydrogen bond interactions found from the 17-






Since 97 is not a drug-like molecule, simplified hybrid inhibitors were subsequently synthesised 
to improve bioavailability and in vivo stability. The adenosine moiety was replaced with 
substituted aniline linked to E2 via saturated alkyl chain to produce compounds 98a-98c (Figure 
17).
130
 Compound 98b bearing a carboxylic acid moiety in the aniline ring showed 90% 
inhibition at 1 M concentration, thus exhibiting approximately the same potency as EM-1745 
97. Compounds 98a and 98c were less potent, with only 32% and 16% inhibition, respectively, 
at 1 M concentration. Carboxylic acid is a bioisostere of the NADPH phosphate, which could 
explain the better inhibitory potency of 98b. Compound 98b was less active at lower (0.1 M) 
concentration, providing only 56% inhibition as compared with the 90% inhibition achieved with 







                                                                                                                      40
2.3 Non-steroidal inhibitors of 17-HSD1 
 
Drug discovery efforts to date have mostly concentrated on modifications of steroidal 
structures;
62
 much less work has been published on non-steroidal inhibitors of 17-HSD1. As 
compared with inhibitors based on steroidal structures, non-steroidal compounds could have 
advantages of synthetic accessibility, drug-likeness, selectivity and non-estrogenicity.  
 
 
2.3.1 Organotin compounds and carotenoids 
 
Although the investigations to be described below are not connected with drug discovery efforts, 
they demonstrate the versatility of studies related to 17-HSD1 inhibition. Organotin compounds 
are environmental contaminants suspected of being endocrine disruptors. Triphenyltin (Ph3SnH), 
the major organotin in human blood, exhibits dose-dependent inhibition of placental 17-HSD1 
with an IC50 value of 10.5 M.
131
  Other sex steroid metabolising enzymes are inhibited to 
greater extent, e.g. 17-HSD3 and aromatase with IC50 values of 4.2 M and 1.5 M, 
respectively. It was proposed that organotins interact with cysteine residues, and this was 
supported by the compensatory effect of dithioerythritol (2R,3S-1,4-dimercapto-2,3-butanediol) 
on the triphenyltin induced inhibition. Contrary to this, a more recent study
132
 showed 17-
HSD1 reductive activity and mRNA transcription in human choriocarcinoma JAr cells to be 
enhanced by Ph3SnH and other organotins, and thus Ph3SnH at 10-100 nM concentration to be a 
potential stimulator of E2 biosynthesis in human placenta.  
 
Palm oil carotenoid concentrate, which mainly consists of -carotene (41.9%) and -carotene 
(51.7%), was found at 1 M concentration to inhibit E1 to E2 conversion by approximately 67% 
in MCF-7 cell line.
133
 On the other hand, at 10 M concentration the concentrate had a strong 
stimulatory effect on the reductive activity. The oxidative activity (E2 to E1) was not affected. 
Trans-retinoic acid showed no inhibitory activity against stimulated E2 formation. It should be 
noted that inhibition of 17-HSD1 activity by carotenoids may occur through an anti-oxidant 
effect on the co-factors.  
 
 
2.3.2 Phytoestrogens and related compounds 
 
After steroid derivatives, phytoestrogens are the most studied 17-HSD1 inhibitor class. 
Phytoestrogens are a group of natural phenolic compounds, including flavonoids, isoflavonoids, 
coumestans and lignans, which possess a wide variety of biological activities (Figure 18).
134
  































































Figure 18. Phytoestrogen structures used in 17-HSD1 inhibition studies. 
 
 
Phytoestrogens can be obtained from diet, e.g. from vegetables and berries, and are currently of 
interest as dietary supplements. A number of phytoestrogens have been demonstrated to inhibit 
various isoforms of 17-HSD,135,136 as well as other steroid metabolising enzymes, in several 




 have evaluated several phytoestrogens and related compounds 
as 17-HSD1 inhibitors, using purified placental 17-HSD1 and T-47D cell lines (Table 6). 
Coumestrol 99 at 1.2 M and 0.12 M concentration was the most promising the inhibitor of  the 
purified enzyme with 82% and 51% 17-HSD1 inhibition,* respectively.138 Unfortunately 
coumestrol was also found to be highly estrogenic. In general, flavones (100) were better 17-
HSD1 inhibitors than flavanones (101), which in turn were better than the corresponding 
isoflavones (102). Of the 14 flavones tested at 1.2 M concentration, kaempferide 100a, acacetin 
100b and fisetin 100c showed best activity against 17-HSD1 with 73-53% inhibition.139 At the 
same concentration the isoflavones genistein 102a and daidzein 102b showed moderate 32-37% 
inhibition. The inhibitory activities were similar, although less effective, in wild type T-47D and 
17-HSD1 cDNA transfected T-47D21 cells. Hydroxy groups at C5 and C7, and a hydroxy or 
methoxy group at C4’ seemed to be important structural features for the biological activity 
(Table 6). Mycotoxin zearalenone 103, coumarin and diethylstilbestrol 11, all potent estrogens, 
did not show inhibition. Plant sterols -sitosterol and -sitostanol exhibited moderate activity 
against purified 17-HSD1 with approximately 31% inhibition at 1.2 M concentration.138 
 
*Mäkelä and co-workers reported the biological activity as  E1 to E2 conversion%, which here is 
converted to inhibition% (inhibition% = 100 – conversion%). 
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 Table 6. The most potent phytoestrogens and their 17-HSD1 inhibition.138,139,141,143 





 Compound Structure C3 C5 C7 C3’ C4’ 1.2 M M 
99 Coumestrol Coumestan      82  8 0.2 
100a Kaempferide Flavone OH OH OH  OMe 73  8  
100b Acacetin Flavone  OH OH  OMe 62  4  
100c Fisetin Flavone OH  OH OH OH 53  9  
100d Galangin Flavone OH OH OH   41  7  
100e Apigenin Flavone  OH OH  OH 42  18 0.3 
100f Kaempferol Flavone OH OH OH  OH 42  21 - 
100g 7-OH-Flavone Flavone   OH   35  5 0.9 
100h Luteolin Flavone  OH OH OH OH -11  5 0.6 
101a Naringenin Flavanone  OH OH  OH 48  11 15 
102a Genistein Isoflavone  OH OH  OH 37  30 1.0 
102b Daidzein Isoflavone   OH  OH 32  10 10 
[a] For the numbering and structure of the flavonoid skeleton see Figure 18. [b] Measured on purified 
placental 17-HSD1. Inhibition% = 100 – conversion%. [c] Measured on human microsomal 17-HSD1.  
 
 
Genistein 102a and coumestrol 99 showed some selectivity towards17-HSD1, whereas the 
flavones
 
kaempferol 100f, kaempferide 100a and galangin 100d were not selective, also 
inhibiting 17-HSD2 activity in PC-3 prostate cancer cells.139  
 
Studies on phytoestrogens and 17-HSD1 inhibition have also been performed with use of 
placental microsomes. Le Lain et al.
140
 found flavonoids to be weak inhibitors (IC50 values >18 
M) of microsomal 17-HSD1 type activity. In more recent studies by Le Bail and co-
workers,
141,142,143
 flavonoids and coumestrol 99 showed relatively high inhibitory activity against 
microsomal 17-HSD1 from human placenta (Table 6). Again coumestrol 99 was the most 
potent phytoestrogen with an IC50 value of 0.2 M; medicarpin 104 with a related structure had 
an IC50 value of >50 M. In the flavonoid series the hydroxy group at C7 was essential for the 
activity, as 7-methoxyflavone was inactive. Apigenin 100e was the most potent flavonoid with 
an IC50 value of 0.3 M.  In addition, the inhibitory activities of 12 chalcones (105) lacking the 
heterocyclic ring C were measured.
142
 4-Hydroxychalcone was the most potent chalcone with a 
moderate IC50 value of 16.0 M.  Placental microsomes can be considered an unusual assay for 
17-HSD1 since they are usually associated with 17-HSD2 expression and activity;144 on the 




In MCF-7 cells, which are known to have low 17-HSD1 expression,46,59 genistein 102a and 
mammalian lignan enterolactone 106, but not enterodiol, showed 59% and 84% 17-HSD1 
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inhibition, respectively, at high 50 M concentration.145 Also the commercial aromatase inhibitor 
4-hydroxyandrostene-3,17-dione exhibited weak 17-HSD1 inhibition. In another study,146 24 h 
exposure of MCF-7 cells to 100 nM of genistein 102a did not affect the conversion of E1 to E2. 
However, 48 h exposure resulted in elevated 17-HSD2 activity and expression. Genistein 102 
and apigenin 100e also weakly inhibit 17-HSD1 activity in primary cultures of human 
granulosa-luteal cells.
147,148
 Surprisingy, synthetic 7-hydroxyflavones with small substituents at 
C4’ (e.g. halogen, Me, -OMe, -NH2, -NO2,) as well as genistein 102b failed to show any 17-





It has recently been proposed that 17-HSD from the fungus Cochliobolus lunatus (17-
HSDcl)
150
 could act as a model enzyme for the SDR superfamily, even though it possesses only 
21.2% and 18.1% sequence identity with human 17-HSD1 and 17-HSD2, respectively.151 This 
readily available enzyme might be useful in preliminary screening of compounds in a fast and 
low-cost spectrophotometric assay not requiring radioactive ligands. The most potent inhibitors 
of the reductive pathway of 17-HSDcl are reportedly coumestrol 99, kaempferol 100f and 
flavones hydroxylated at C3, C5, C7 and C4’ positions (IC50 values 1.2–4.8 M). This 
substitution pattern was also preferred in 17-HSD1 inhibition, although molecular modelling 
studies for kaempferol 100f suggested a different binding orientation from that of human 17-
HSD1.
151
  Possible applications of 17-HSDcl in identifying new 17-HSD1 inhibitors remain to 
be clarified.  
 
In silico approaches have been used to investigate the binding modes of phytoestrogens to 17-
HSD1. When kaempferol 100f was docked into 17-HSD1–equilin complex (PDB code 1EQU) 
it occupied the steroid binding domain.
151
 The hydroxy group at C7 pointed towards the catalytic 
region (Tyr155 and Ser142), and the C4 carbonyl and C5 hydroxy groups were facing Tyr218 
and Ser222. The hydroxy group at C4’ was in close proximity to Glu282 and His221, which was 
suggested to explain why 4’-hydroxyflavones like 100f are good inhibitors in the flavonoid 
series. Coumestrol 99, docked into the 17-HSD1–E2–NADP+ complex (PDB code 1FDT), 
superimposed well with E2, and the peripheral phenolic hydroxyls in 99 were suggested to form 
the same hydrogen bond interactions as those in E2.
152
 This similar binding mode of coumestrol 
99 with E2, with an additional interaction with Tyr218, could explain the good inhibitory activity 
of coumestrol. Genistein 102a and apigenin 100e were also showed to occupy the ligand binding 
domain. In addition to the docking study, the activity data of Mäkelä and co-workers
138,139 
was 
utilised to derive a pharmacophore for the active site of 17-HSD1.152 
 
In conclusion, several studies have established that phytoestrogen structures, especially 
coumestrol 99 and some flavonoids, are capable to bind to the active site of 17-HSD1 and 
inhibit the enzyme activity. Although the estrogenic nature and inadequate selectivity of these 
                                                                                                                      44
compounds prohibits their use as 17-HSD1 inhibitors as such, it is suprising that no true drug 
discovery efforts exploiting phytoestrogens as lead compounds have been reported. The 




2.3.3 Gossypol derivatives: inhibitors targeted to the Rossmann fold 
 
Gossypol 107, a bioactive polyphenol found in cottonseed, and four of its synthetic derivatives 
have been tested against purified placental 17-HSD1 (Figure 19).155 The compounds were 
targeted to the Rosmann fold, i.e. the cofactor binding domain of the enzyme (see section 1.1), as 
gossypol and its derivatives have been shown to inhibit other enzymes binding dinucleotides.
156
 
In nature, gossypol 107 occurs as a mixture of enantiomers as a result of restricted rotation 
around the central C–C bond. At 25 M concentration gossypol 107 showed a minor (<10%) 
inhibitory response in the oxidative direction (E2 to E1, pH 9.2) of 17-HSD1.155 The synthetic 
derivatives gossylic lactone 108a and gossylic iminolactone 108b showed enhanced activity with 
80-90% inhibition and IC50 values of 2.2 M and 4.3 M, respectively, and demonstrated 































Figure 19. Gossypol and its synthetic derivatives. 
 
 
Docking studies indicated that 108a occupies the cofactor-binding region via up to eight 
hydrogen bond interactions. The lactone 108a was utilised as a lead compound, and active site 
analysis suggested that replacing the C5 isopropyl with a butylene group linked to a substrate 
mimetic (C and D rings of E2) would result in a probable dual-site inhibitor 109. This study
155
  
showed that 17-HSD1 can be inhibited by compounds targeting the cofactor binding domain. 
This approach is likely to suffer from lack of selectivity, however, as the Rossmann fold moiety 
is found in numerous other enzymes as well.  
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2.3.4 Phenyl ketones and derivatives of benzofuranone, benzopyranone and tetralone 
 
Derivatives of benzofuranone 110a-110d, benzopyranone 111-112 and tetralone 113, which can 
be considered to structurally resemble flavonoids, have been patented as 17-HSD inhibitors 
(Figure 20).
157,158
 These compounds inhibit NADPH dependent conversion of E1 to E2 in human 
placental microsomes. Inhibition of 17-HSD1 up to 77% has been reported for compounds 110-
113.  The inhibitor concentration used in the activity measurements was not reported, and thus 
evaluation and comparison of the inhibitory potency of these compounds is not possible. In the 
benzofuranone series 110, R
4
 methoxy substituent seemed to be unfavoured, whereas acetylation 
of the phenolic hydroxy group seemed to slightly improve the activity. In general, the 














113  X = CH2  (50%) 
111  X = O      (58%)
O
HO X
114a X = Cl   (IC50 14.8 M) 
114b X = Br   (IC50 14.6 M)




     R2 = Alkyl
     R1 = H, OH, NO2, Halogen
110a R3=OH, R5=H                       (70% )
110b R3=OMe, R5=H                     (72%) 
110c R2=OH, R3=Me, R5=H          (77%) 
110d R2=OMe, R4=OMe, R5=H     ( 2%) 
110d R1=OMe, R3=OMe, R5=H     (69%) 













Figure 20. Examples of benzofuranone, benzopyranone, tetralone and phenylketone based 17-HSD 
inhibitors.
157,158,159,160
 The reported inhibition% (unspecified test concentration) and IC50 values are given 
in parenthesis.  
 
 
4’-Halogenated 2-(phenylmethyl)-6-hydroxy-3,4-dihydronaphthalen-1(2H)-ones 114a-114c 
showed only moderate inhibition of human placental soluble and microsomal 17-HSD1 with 
IC50 values of 14.6-21 M.
159
 These compounds were better 17-HSD3 inhibitors, with IC50 
values of 1.8-8.3 M. Phenyl ketones 115 and biphenyl ketones 116 are reportedly very weak 
inhibitors of 17-HSD1 in testicular micromes.160 The best inhibitors were 1-(4-hydroxyphenyl)-
1-hexanone and 1-[1,1'-biphenyl]-4-yl-1-pentanone with approximately 45% inhibition at 100 
M concentration. 
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Although the structures described above represent attempts to create novel non-steroidal 17-






Subsequent to our findings on non-steroidal 17-HSD1 inhibitors based on a thieno[2,3-
d]pyrimidin-4(3H)-one core,
161
 Solvay Pharmaceuticals reported a series of 8-hydroxy-
benzothieno[2,3-d]pyrimidin-4(3H)-ones with various substituents at C2 and N3 positions as 
17-HSD1 inhibitors (Table 7).40,162 Compounds 117-118, at 100 nM concentration, were found 
to be potent inhibitors of rec17-HSD1 with 82-94% inhibition in a protein based assay.  On the 
basis of docking studies it was postulated that the pyrimidinone moiety and the phenolic hydroxy 
group at C8 are responsible for the 17-HSD1 inhibitory activity, while the substituents at 
positions C2 and N3 of the pyrimidinone ring could influence the selectivity. With 117e, for 
example, the hydroxy group pointed towards the catalytic region and was within close proximity 
of Ser142 and Tyr155, while the benzyl ring was placed close to His221.  
 
With compounds 117a-117f, which have a trimethoxyphenyl group at position C2, variation of 
the R
1
 substitution had little influence on the inhibitory activity against rec17-HSD1. The 
selectivity over rec17-HSD2 was slightly improved with alkyl substituents. A more dramatic 
effect was seen in MCF-7 cells expressing 17-HSD1, where the R1 substitution seemed to affect 
the cell permeability (Table 7). Overall, with compounds 117a-117f the inhibitory activity was 
significantly reduced in a cell based assay. Here the benzyl derivative 117d was the most potent 
inhibitor with 52% inhibition at 1 M concentration. With 117f (1 M) the inhibition was 
reduced to just 14%, as compared with the 95% inhibition found in a protein based assay. 
Varying the R
3
 substitution in N-benzyl derivatives 118a-118c did not affect the activity against 
rec17-HSD1, but it had an impact on the selectivity as well as cell permeability. Bulky C2 
substituents like the trimethoxyphenyl group in 117b and 117d seemed to improve the selectivity 
towards 17-HSD1. This substitution was also favoured in the cell based assay, indicating better 
cell membrane permeability of these compounds. Compound 119a exhibited only weak 
inhibition of rec17-HSD1, and the addition of an n-butyl or benzyl group as R5 substituent in 
119c and 119d resulted in loss of the activity, but n-butyl as R
4
 seemed to be tolerated. An IC50 
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Table 7. 8-Hydroxy-benzothieno[2,3-d]pyrimidin-4(3H)-ones with variable substituents at C2 and N3 




















117a  R1 = (1-Propyl)  R2 = H
117b  R1 = (2-Butyl)    R2 = H
117c  R1 = (2-Propyl)  R2 = H
117d  R1 = Ph             R2 = H
117e  R1 = Ph             R2 = Br
117f  R1 = (5-Bromo-2-furanyl) R2 = H
R2
119a  R4 =H          R5 = H
119b  R4 = Butyl    R5 = H
119c  R5 = Butyl     R4 = H
119d  R5 = Benzyl  R3 = H
118a   R3 = (2-Thienyl)
118b   R3 = (2-Methyl-1-propenyl)









              Inhibition % of 17-HSD1 and 17-HSD2 




 Rec17-HSD1 Rec17-HSD2 17-HSD140 17-HSD2162 
Compd 100 nM
b 
 1 Mb  1 Mb 1 Mb  1Mb 
117a 86 95 26 38 31 
117b 91 94 43 47 24 
117c 93 98 47 34/21
c 
15 
117d 94 99 64 52 22 
117e 87 95 47 67/25
c 
20 
117f 90 95 58 14 15 
118a 83 89 89 15 55 
118b 82 97 87 52  
118c 89 95 77 25 26 
119a 33 78    
119b 52 81    
119c 9 27    
119d 5 26    
[a] MCF-7 cell line stably expressing one of the respective 17-HSD isoforms. [b] Inhibitor 





Modifications of the benzothieno moiety, for example in the potent inhibitor 117d, did not yield 
better 17-HSD1 inhibition in the cell based assay (Figure 21).162 Acetylation or methylation of 
the phenolic hydroxyl at C8 gave compounds 120 and 121 with 35% and 21% inhibition at 1 M 
concentration, respectively, whereas the removal of the C8 phenolic hydroxyl from 117e resulted 
in complete loss of the activity. The 8,9,10,11-tetrahydrobenzothieno derivatives 122-124 also 
showed reduced activity.  
 































The efficacy of compound 117e has been additionally proven in vivo in a nude mouse model. 
Four-week subcutaneous administration of 117e (5 M/kg/day) resulted in 54% reduction in 
tumour (MCF-7 cells expressing human 17-HSD1) size as compared with the non-treated 
controls.
40
 In addition, compound 117e did not show estrogenic activity in a rat uterus weight 
test. Although compound 117e was effective in vivo it should be noted that all the compounds 
tested at 1 M concentration in a cell based assay showed significantly reduced activity as 
compared with rec17-HSD1 assay, indicating poor bioavailability of these compounds. Also in 




2.4 Summary of 17-HSD1 inhibition 
 
As described above, many potent 17-HSD1 inhibitors have been identified in recent years. 
Table 8 lists representative 17-HSD1 inhibitors with good affinity to the enzyme. To compare 
the inhibitory potencies of these compounds is difficult if not impossible, however, as various 
biological assays, with different substrate and enzyme concentrations, have been employed. The 
inhibitory potencies have been also expressed in various ways, though in general, IC50 and Ki 
values are considered to be the most laboratory-independent. To allow reliable comparison, the 
inhibitors should be tested in parallel in the same assay. Moreover, a feasible clinical candidate 
should not only be a potent and selective 17-HSD1 inhibitor but also possess suitable 
pharmacological properties. For example, the human recombinant 17-HSD1 enzyme is an 
example of an assay that offers reliable information on direct interaction of the inhibitor with the 
enzyme but it does not give information about cell permeability or possible secondary 
metabolism of the compounds. 
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Table 8. Selected 17-HSD1 inhibitors with good biological activity.  


































































73% at 1.2 M - 










88% at 1.2 M 
 
- 





















94% at 0.1 M 








[a] Transfected with 17-HSD1 cDNA 
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Currently there are no 17-HSD1 inhibitors on the market, and although patent applications 
relevant to 17-HSD1 inhibition have recently been published, clinical trials for potential 
inhibitors have not yet been reported. Clearly there is a demand for novel 17-HSD1 inhibitors. 
Small non-steroidal molecules to be used as 17-HSD1 inhibitors have so far received little 
attention, but with the aid of molecular modelling novel chemical entities could be found. 
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AIMS OF THE STUDY 
 
The primary aim of the present study was to develop new non-steroidal 17-HSD1 inhibitors for 
the treatment of breast cancer and other hormone-dependent disorders. A tetracyclic thieno[2,3-
d]pyrimidin-4(3H)-one derivative that had been identified as a potent lead compound was used 
as a template for structural modification. The screening strategy comprised evaluation of the 
biological activity of the potential inhibitors against 17-HSD1 in recombinant enzyme and cell 
based assays. The selectivity over isoform 17-HSD2 was of interest. In connection with the 
drug discovery efforts, a further aim was to investigate the chemical properties of the fused 
(di)cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones.  
 
 
More specifically, the aims of the study were 
 
1. To develop an efficient synthetic route for the lead compound (I, II) 
 
2. To synthesise a molecule library based on the lead compound with the aim of improving 
biological activity, and to study the QSAR of the 17-HSD1 inhibitors (II, V)  
 
3. To investigate the reactivity and structure of fused (di)cycloalkeno thieno[2,3-
d]pyrimidin-4(3H)-ones (IV) 
 
4. To clarify the reaction mechanism of Vilsmeier haloformylation (III) 
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  RESULTS AND DISCUSSION 
 
At the start of our multidiciplinary reasearch project, a commercial library of 1000 compounds 
was evaluated against 17-HSD1. 1,2,7,8,9,10,11,13-Octahydro-13-oxo-4-(phenylthio)-
1]benzothieno-[2',3':4,5]pyrimido[1,2-a]azepine-3-carboxaldehyde*,163 125 (Figure 22) was 
identified as a potent inhibitor and selected as lead compound for 17-HSD1 inhibitor 
development (Figure 23). Although compound 125 was commercially available in milligramme 













Figure 22. The lead compound 1,2,7,8,9,10,11,13-octahydro-13-oxo-4-(phenylthio)-1]benzothieno-
[2',3':4,5]pyrimido[1,2-a]azepine-3-carboxaldehyde* 125 and the labelling of the rings. 
 
 
Chapters 3 describes the synthesis and reactivity of 17-HSD1 inhibitors based on a thieno[2,3-
d]pyrimidin-4(3H)-one core. The mechanism of Vilsmeier haloformylation reaction was revised 
in connection to the reactivity studies and this is reported in section 3.4. The biological activity 
and the binding mode of selected thieno[2,3-d]pyrimidin-4(3H)-one based 17-HSD1 inhibitors 










* Chemical Abstracts Service (CAS) name 
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3.1 Fused dicycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones 
 
Thieno[2,3-d]pyrimidin-4(3H)-ones are a large group of organic heterocyclic compounds where 
a thiophene ring is fused at its 2,3 position to the 5,6 position (d bond) of a pyrimidin-4(3H)-one 
ring. More than 62,800 compounds have been registered to contain this fused heterocyclic 
moiety.
164











Figure 23. The general structure of fused dicycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones. 
 
 
Dicycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones, such as compound 126, are traditionally 
synthesised from ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 127 in a 
condensation reaction with lactams
165
 or O-alkyl lactam ethers.
167
 The thiophene 127 and its 
analogues can be synthesised from cyclic ketones in a Gewald reaction (Scheme 1).
171,172
 





 (Staphylococcus aureus, Bacillus subtilis) and 
antiinflammatory
168
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3.2 Development of a synthetic route for the lead compound
I,II 
 
The lead compound 125 was submitted to a retrosynthetic analysis, and the commercially 
available ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 127 was found to be 
a logical starting material. A four-step synthetic route was designed (Scheme 2).
I
 Since the 
synthetic route was to be employed in the synthesis of derivatives of the lead compound, strong 
emphasis was put on the optimisation of the reaction conditions. First, POCl3 catalysed 
cyclisation of 127 with -caprolactam was optimised to produce the tetracyclic dicycloalkeno 
thieno[2,3-d]pyrimidin-4(3H)-one core 126 in 90% yield. This cyclisation with POCl3 as catalyst 
has earlier been reported to give 126 in 50% yield,
165
 but careful optimisation of the amount of 
the catalyst and the reaction conditions provided significantly improved yield.
I,II
 The published 
procedure
166
  for the oxidation of the thiophene moiety -position in 126 with K2Cr2O7 gave 128 
in average 20% yield. In the second step, the yield of 128 was improved to 54% by using excess 
of PCC–Celite as the oxidising reagent.I,IV The oxidation of 126 with the seldom used K2S2O8–
CuSO4
173,174




















































In step three, Vilsmeier haloformylation
175
 of the keto group was employed to produce the 
corresponding conjugated -chlorovinylaldehyde 129.I,II Compound 129 was considered to be a 
crucial intermediate in the synthetic route. Surprisingly, overnight stirring of ketone 128 with 
excess of DMF–POCl3 (Vilsmeier reagent) led to the formation of the corresponding -
chloroalkene 130 and only a small amount of the desired haloformylation product 129. However, 
prolonged reaction time produced the -chlorovinylaldehyde 129 in 78% yield. Monitoring of 
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the reaction by TLC and 
1
H NMR indicated that the reaction proceeds via the -chloroalkene 
130. Haloalkene formation with Vilsmeier reagent has occasionally been reported in 
literature.
176,177,178,179,180
 In general, these chloroalkenes were considered to be abnormal 
sideproducts, but not intermediates, although Vilsmeier reagents are known to formylate 
activated double bonds.
175,181
 This observation of -chloroalkene formation led to the 
investigation and revision the reaction mechanism of Vilsmeier haloformylation (see section 
3.4).
III
 In the final step of the synthetic route for the lead compound 125, the aromatic thioether 
moiety was introduced into 129 in an addition–elimination reaction of thiophenol under basic 




In conclusion, an efficient four-step synthetic route, starting from the commercially available 
ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 127, was developed for the 
lead compound 1,2,7,8,9,10,11,13-octahydro-13-oxo-4-(phenylthio)-1]benzothieno-
[2',3':4,5]pyrimido[1,2-a]azepine-3-carboxaldehyde 125. Overall yield was 42%. This synthetic 




3.3 Structural modifications of the lead compound: synthesis of derivativesI,II 
 
After the development of a synthetic route for the lead compound 125, derivatives were 
synthesised with the aim of improving the biological activity and investigating the QSAR of the 
thieno[2,3-d]pyrimidin-4(3H)-one based 17-HSD1 inhibitors.I,II Four sites were chosen for 
structural alterations of  125: rings A and D (homologation), the aldehyde functionality and the 







     RING D
-homologation
-substitution
     RING A
-homologation
-aromatisation
 THIOETHER SIDE CHAIN
-aromatic vs. aliphatic
-hydrogen bond donors/acceptors





Figure 24. Modification sites on the lead compound. 
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3.3.1 Homologation of the cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-one core 
 
Homologation of the fused thieno[2,3-d]pyrimidin-4(3H)-one skeleton was investigated in order 
to identify the optimal core for 17-HSD1 inhibitors. The same synthetic route as for the lead 
compound was employed in the synthesis of homologues 131a-131c with a thiopropyl side chain 
in the ring A (Scheme 3). Five to eight membered lactams were fused with 2-amino-4,5,6,7-
tetrahydrobenzo[b]thiophene-3-carboxylic acid  ethyl ester 125 to give the ring D homologated 
derivatives 132a-132c in 76-90% yields. Similarly, cyclisation of ε-caprolactam with 2-amino-
5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid ethyl ester and with 2-amino-
5,6-dihydro-4H-cyclopenta-[b]thiophene-3-carboxylic acid  ethyl ester gave the ring A 
homologated derivatives 132d and 132e, respectively. As with compound 126, K2S2O8–CuSO4 
was the preferred oxidant for the homologated derivatives, producing the oxidised derivatives 




























132a n=2, m=1 
132b n=2, m=2 
132c n=2, m=4 




133a n=2, m=1 
133b n=2, m=2 
133c n=2, m=4 
133d n=3, m=3 
133e n=1, m=3
134a n=2, m=1 
134c n=2, m=4 
134d n=3, m=3
131a n=2, m=1 








Scheme 3. Homologation of the cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones. 
 
 
Unexpected difficulties emerged in the Vilsmeier haloformylation step when ketones 133a and 
133b, having a five or six membered cycloalkeno ring fused to the pyrimidinone moeity, were 
treated with DMF–POCl3 (see Scheme 3). Complex mixtures of inseparable products, containing 
only small amounts of the desired -chlorovinylaldehydes, were obtained under the same 
reaction conditions as produced compound 129 in good yield with only traces of side products. 
Various Vilsmeier reagents and reaction conditions were tested without significant improvement 
in the outcome of the reaction. For example, with 133a, after optimisation of the reaction 
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conditions and a tedious chromatographic purification, a moderate 42% yield of the -
chlorovinylaldehyde 134a was obtained. However, 133c, which has an eight membered ring 
fused to the pyrimidinone moiety, produced the corresponding -chlorovinylaldehyde 134c in 
60% yield under the original reaction conditions. Vilsmeier haloformylation of ketones liberates 
HCl, which is considered to catalyse the keto–enol tautomerism required for the reaction.175  
Treatment of 133a and 133b with HCl in CH2Cl2 was found rapidly give rise to insoluble imine 
salts. The salt formation was suspected to partly contribute to the complex reactivity of 133a and 
133b with POCl3–DMF. To test this hypothesis, the reaction was performed in an ionic liquid. 
Since the use of an ionic liquid as solvent in Vilsmeier haloformylation has not been reported in 
the literature, the applicability was first tested with a model compound. In [bmim][NTf2] the 
model compound 2-butanone reacted with POCl3–DMF to give 3-chloro-2-methyl-2-butenal as a 
mixture of diastereomers in good yield. Compounds 133a and 133b produced similar mixtures to 
those produced in organic solvents, however. 
 
The different reactivities of the homologated compounds 133a-133b in the Vilsmeier 
haloformylation were also suspected to arise from conformational biases in the fused ring 
structures. This led us to investigate the structures of 133a-133e and 128, and their reactivity 
towards a similar electrophilic reagent, DMFDMA (see section 3.5). As has been shown, the 
amidine -position is activated and a Vilsmeier reagent furnishes C9 enamines from 6,7,8,9-
tetrahydro-4H-pyrido[1,2-a]pyridine-4-ones.
182
 This cannot be the sole explanation of the 
different reactivities of 133a and 133b, however, since when non-oxidised 132a and 132b are 
exposed to the Vilsmeier haloformylation conditions, starting material is recovered. 
 
In addition to the tetracyclic cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones 131a-131d, a 
tricyclic derivative 135 was synthesised in order to investigate the importance of hydrophobic 
ring D for the biological activity (Scheme 3).
II
 Again the same synthetic route (Scheme 2) was 
employed as for the lead compound, with N-methylacetamide supplying the starting material. 
For this tricyclic skeleton the Vilsmeier haloformylation step proceeded in high yield and purity. 
When an additional methyl group was introduced to the C2 position of the amidine ring, the 
Vilsmeier haloformylation again becomes unpropitious, indicating that the problems in the 
reaction do indeed arise from the amidine -position. 
 
The biological test performed on the homologated derivatives and with compound 136b (Figure 
25),
II
 suggested that the original dicycloalkeno thieno[2,3-d]pyrimidin-4(3H)-one core, with a 
seven membered ring fused to the pyrimidone moiety, is ideal for the activity, and this was 
chosen for further structural modifications.  
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3.3.2 Modifications on rings A and D of the lead compound 
 
To investigate the influence of the bulky thioether side chain in ring A of 125 on the biological 
activity, nine derivatives, 136a-136i, with an aliphatic thioether side chain and 12 derivatives, 
137a-137l, with an aromatic thioether side chain were synthesised (Figure 25).
I,II
 The same 
synthetic route was employed as for the lead compound (Scheme 2). In addition, functional 


























a = b =
c = d =
e = f = g =
h = i =
a = b = c =
d = e = f =
g = h = i =
j =
k = l =
 
 
Figure 25. Derivatives of the lead compound bearing a modified thioether moiety.
I,II
 The dashed lines   
indicate the point of attachment.
 
 
   
Because it is highly reactive, an aldehyde is not an ideal functional group in a drug molecule and 
it was therefore replaced with a hydroxyl group. Reduction of the aldehyde moiety in 125 and 
136b with NaBH4 gave the corresponding alcohols 138 with retained biological activity. These 
allylic alcohols 138 were relatively unstable, however, and they were rejected (Figure 26). In 
order to produce chemically more stable compounds, derivatives with an aromatic ring A were 
synthesised. The aromatisation of the unsaturated ring A with DDQ produced the 
benzothieno[2,3-d]pyrimidin-4(3H)-one derivatives 139a and 139b in 84-91% yield (Scheme 4). 
Subsequent reduction of the aldehyde functionality with NaBH4 in EtOH gave the desired 
benzylic alcohols 140a and 140b in good yield.  












143 R = -CH2OH
144 R = -COOH
145 R =- CHNOH
138 R1= -CH2OH 
141R1 = -CHNOH
142R1 = -CHCHCOCH3







146 R = -Me
147 R = -CO2Et
148 R = -COOH
O
R2 = -Pr  
 
























136b  R = Pr
125    R = Ph
139a  R = Pr
139b  R = Ph 140a  R = Pr




Scheme 4.  The synthesis of the derivatives of the lead compound with an aromatised ring A. 
 
 
For further studying the binding interactions of these thieno[2,3-d]pyrimidin-4(3H)-one based 
17-HSD1 inhibitors, the aldehyde functionality in 136b or 129 was converted to oxime, 
carboxylic acid or conjugated alkene in straightforward functional group interconversions 
(compounds 141-145, Figure 26).
II
 In addition to the ring A modification, compounds 146-148 
bearing substituents at the C9 position of ring D were synthesised using C5-substituted 





3.4 Haloalkenes as intermediates in the Vilsmeir haloformylation of ketones
III 
 
The unexpected reactivity and -chloroalkene formation with cycloalkeno thieno[2,3-
d]pyrimidin-4(3H)-ones under Vilsmeier haloformylation conditions (see section 3.3.1) led to a 
reconsideration of the reaction mechanism. Investigation of cases of haloalkene formation 
reported in the literature revealed structural similarities. Except for one aberration involving a 
steroidal structure,
183
 in all cases reported
176,177,178,179,180
 the reactive carbonyl group was 
conjugated to a strong electron donating group. This conjugation was suspected to contribute to 
the haloalkene formation under Vilsmeier haloformylation conditions, and to confirm this, a 
study was performed with substituted aryl ketones as model compounds.
III 
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As postulated, 1 equiv. of Vilsmeier reagent (DMF–POCl3) furnished 1-aryl-1-haloalkenes 150a-
150i from the corresponding aryl ketones 149a-149i along with traces of -halovinylaldehydes 
151 as a side product (Scheme 5).
III
 The reaction requires a strong electron donating group, e.g. 
methoxy at the ortho- and/or para-position to the carbonyl group. The electron donating ability 
of the aromatic substituent determines the requisite reaction time and temperature as well as the 
conversion. As expected, unsubstituted and meta-substituted arylketones expectedly failed to 



















150a  R1 = OMe,  R2 = OMe, R3=H, X=Cl
150b  R1 = OMe,  R2 = OMe, R3=Me, X=Cl
150c  R1 = NMe2, R
2 =H, R3=H, X=Cl
150d  R1 = NMe2, R
2 =H, R3=Me, X=Cl
150e R1 = H, R2 =NMe2, R
3=H, X=Cl
150f  R1 = OMe,  R2 = R3= -(CH2)2-, X=Cl
150g R1 = OMe,  R2 = OMe, R3=H, X=Br
150h R1 = OMe,  R2 = OMe, R3=Me, X=Br
150i  R1 = NMe2, R
2 = H, R3=Me, X=Br  




NOESY and 1D ROESY NMR experiments established the configuration of the double bond to 
be exclusively Z for the chloroalkenes 150a-150e. Small amounts (<10%) of the E-isomer were 
detected in the 
1
H NMR spectrum when DMF–POBr3 was used. If the formation of the Z-isomer 
is blocked, as in the case of 6-methoxytetralone 150f, the E-isomer is obtained. The 
bromoalkenes 150g-150i readily cleaved HBr to form the corresponding acetylenic compounds, 
and overall the haloalkenes 150a-150i were relatively unstable. Analytically pure samples of the 
(Z)-1-aryl-1-haloalkenes were obtained chromatographically with use of neutral Al2O3 as a 
stationary phase. 
 
The (Z)-1-aryl-1-haloalkenes proved to be intermediates in the Vilsmeier haloformylation. -
Halovinylaldehydes 151a-151i were obtained from 149a-149i with excess of Vilsmeier reagent, 
and the haloalkene intermediates were detected by monitoring the reaction on TLC or by 
1
H 
NMR. Similarly, when (Z)-1-aryl-1-haloalkenes 150a-150i were treated with Vilsmeier reagent, 
-halovinylaldehydes were obtained as a mixture of isomers. This results offers solid evidence 
that haloalkenes are primary intermediates in the Vilsmeier haloformylation reaction of suitably 
substituted aryl ketones 149a-149i. The same reaction pathway is applicable to more complex 
molecules such as the oxidised cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones 133a-133d and 
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128, where there is a similar conjugation to the reactive carbonyl group. An alternative reaction 
mechanism is thus available in certain Vilsmeier haloformylations,
III
 in competition with the 




The origin of the high stereoselectivity of the reaction was investigated with quantum-chemical 
density-functional calculations.
III
 The energy difference between the Z- and E-isomers of the 
products 150b, 150d, 150g and 150i was calculated (B3LYP/TZVP), and the relative energies 
between the isomers were found to correlate reasonably well with the selectivity of the isomer. 
However, the energy differences were not large enough to be the sole explanation for the 
selectivity. Utilising the final step of our postulated reaction mechanism (Scheme 6), we 
constructed a potential energy surface (PES) for species 150d* by scanning the torsion angle 
C1'–C1–C2–C3 and the bond length of the leaving proton (RI-BP/SVP). From the PES a clear 
pathway towards the Z-isomer can be discerned (Figure 27). From the start the Z-isomer is 
favoured, and the transition to the E-isomer becomes increasingly difficult as the double bond 
character between C1 and C2 in the intermediate 150d
*

































Scheme 6. The reaction mechanism postulated for chloroalkene formation in the reaction of Vilsmeier 
reagents with aryl ketones.
III
 EDG =  electron donating group;  X = Cl, Br 
 
 
In conclusion, it was shown that the Vilsmeier haloformylation reaction can proceed via a 
haloalkene intermediate when suitable conjugation to an electron donating group is present. In 
addition, the haloalkene formation was shown to be highly stereoselective. 
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Figure 27. The potential energy surface for the final deprotonation step for species 150d.III Energies 
relative to the lowest energy conformation for each proton bond length are shown. For the C1'–C1–C2–
C3 torsion angle, 0° corresponds to the E-isomer, 180° to the Z-isomer. The fully relaxed geometry 




3.5 Stereoelectronic effects in the reactivity of dicycloalkeno thieno[2,3-
d]pyrimidin-4(3H)-ones: thermal condensation with DMFDMA
IV 
 
The unexpected results (see section 3.3.1) obtained in the reactions of 133a and 133b with 
DMF–POCl3 (Vilsmeier reagent) raised the question of possible structural biases in the fused 
ring system contributing to the different reactivity. The reactivity of cycloalkeno thieno[2,3-
d]pyrimidin-4(3H)-ones towards electrophilic reagents was investigated with 
dimethylformamide dimethylacetal (DMFDMA). DMFDMA reacts via aza-oxo-stabilised 
carbenium ions and can thus be considered as a reagent related to DMF–POCl3. Activated 
methylene groups, e.g. in carbonyl compounds and imines, react with DMF acetals in a 
condensation reaction. The thermal condensation of DMFDMA with carbonyl compounds 
produces enaminones, which are also intermediates in the direct Vilsmeier haloformylation of 
ketones.
175
 Treatment of enaminones with POCl3 is known to produce the corresponding -
chlorovinylaldehydes,
184
 and it was postulated that this could have been an alternative two-step 
route to the -chlorovinylaldehydes from 133a and 133b. 
 
As it turned out, the condensation reaction of 133a and 133b with 4 equiv. of DMFDMA 
proceeded in high yield and regioselectivity, producing the corresponding conjugated (E)-
enamines 152a and 152b (Scheme 7).
IV
 The result indicated the amidine -position to be more 
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eight membered cycloalkeno rings fused to the pyrimidinone, did not give enamines, but instead 
the corresponding (E)-enaminones 153a and 153b.  
 
The regioselectivity of compounds 128, 133a, 133b and 133e was shown to originate from a 
stereoelectronic effect and to depend on the rate of the amidine–ketene–N,N-acetal 
tautomerism.
IV
 Deuterium exchange experiments showed this tautomerism to be prohibited with 
the larger ring systems (compounds 128 and 133e). For the amidine–ketene–N,N-acetal 
tautomerism to occur, and thus the condensation and deuterium exchange reactions to proceed, 
the C-H bond at the -position must be able to orientate approximately parallel to the amidine 
double bond p orbitals. The crystal structures revealed that, in 133a and 133b the two amidine -
protons (HA and HB) are positioned out of the plane of the ring with respect to the amidine 
double bond, with dihedral angles between 44° and 73° (Table 9, Figure 28),  suggesting 
favourable p orbital interactions. In the crystal structures of 128 and 133e with their larger fused 
cycloalkeno rings, the amidine -proton deviations from 90° dihedral are larger, leading to an 
unpropitious orientation of the  C-H bonds that prohibits the amidine–ketene–N,N-acetal 
tautomerism. In compounds 128 and 133e, the carbonyl -position is more activated than the 
amidine -position, and the enaminones 153a and 153b were the favoured products.  
 
In the tricyclic derivative 154, the amidine -methyl group is freely rotating and the required 
conformation for the tautomerism is readily obtained. According to 
1
H NMR, 155 has two 
rotamers at 27°C due to the restricted rotation of the –NMe2 moiety. An energy barrier (∆G‡) of 
















152a n = 1 95%
152b n = 2 84%
153a  n = 1 85%
153b  n = 2 72%
133a   n = 1
133b   n = 2
128     n = 3
133c   n = 4
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110-120°C
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Figure 28. The superimposed crystal structures of 133a (green) and 128 (orange) demonstrating the 
different conformational orientations of the protons at the amidine -position. The superimposition 




Table 9. The dihedral (torsion) angles and the degree of H/D exchange at the imine -position in 




    
Compound N=C-C-HA N=C-C-HB D exchange
b
 Product Yield 
133a 58.1° 62.4° 68% Enamine    152a 95% 
133b 72.8° 43.9° 75% Enamine    152b 84% 
     128  10.9° 127.5° - Enaminone 153a 85% 
133e 23.2° 139.8° - Enaminone 153b 72% 
[a] Dihedral angles measured from the crystal structures. [b] The H/D exchang% of the amidine -protons 




In conclusion, it was shown that regioselectivity in the reaction of DMFDMA with fused 
cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones 128, 133a, 133b and 133e is controlled by the 
stereoelectronic effect at the amidine -position in ring D. This observation contributes to the 
understanding of reactivity of fused cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones towards 
certain electrophilic reagents. The stereoelectronic effect is likely to contribute to the unexpected 
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4. BIOLOGICAL ACTIVITY AND BINDING MODE OF THIENO[2,3-
d]PYRIMIDIN-4(3H)-ONE BASED 17-HSD1 INHIBITORS 
 
 




The screening strategy for thieno[2,3-d]pyrimidin-4(3H)-one based inhibitors included 
evaluating their biological activity against 17-HSD1 in a recombinant protein and for selected 
compounds also in a cell based assay. The compounds were also tested against 17-HSD2 and 
17-HSD3 to evaluate their selectivity. In addition, the possible estrogenity of the compounds 
was investigated. 
 
The lead compound 125 at 1 M concentration showed promising activity in both rec17-HSD1 
and in cell based 17-HSD1 assays, with 85% and 41% inhibition, respectively, and selectivity 
over 17-HSD2 and 17-HSD3. Homologation of ring A or ring D did not improve the 
inhibitory activity and thus the original tetracyclic skeleton with a seven membered cycloalkeno 
ring D was chosen for further structural modifications.
II
 The aldehyde functionality and the 
thioether moiety were shown to be important structural features for the biological activity since 
the cyclised intermediates, e.g. compounds 126-130, failed to show good inhibitory activity 
against 17-HSD1.I,II  
 
Most of the derivatives of the lead compound with a modified thioether moiety in ring A showed 
good activity against rec17-HSD1 at 100 nM and 1 M concentration.II Aromatisation of ring A 
and reduction of the aldehyde moiety seemed to slightly improve or retain the biological activity 
as compared with the non-aromatic counterparts. However, introduction of an amino or a 
carboxylic acid group to the C4’ position of thiophenyl side chain led to loss of activity 
(compounds 137g and 137j). The most potent inhibitor identified in this study was 4-(3-
hydroxyphenylthio)-1,2,7,8,9,10,11,13-octahydro-13-oxo-1]benzothieno[2',3':4,5]pyrimido[1,2-
a]azepine-3-carboxaldehyde 137k,  with 94% and 97% inhibition of rec17-HSD1 at 0.1 M and 
1 M concentration, respectively.II  
 
Representative inhibitor structures and their 17-HSD1, 17-HSD2 and 17-HSD3 inhibition 
data are presented in Table 10.  
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Table 10. Selected examples of thieno[2,3-d]pyrimidin-4(3H)-one based 17-HSD1 inhibitors, and their 
biological activity.
I,II 
  17-HSD  inhibition% in a protein and/or cell based assaya 
  rec17-HSD1 17-HSD1c rec17-HSD2 17-HSD3c 
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Table 10. Continues 
 
  rec17-HSD1 17-HSD1 rec17-HSD2 17-HSD3 
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 [a] Biological activity measurements were performed at Hormos Medical Ltd., Turku, Finland [b] Not  
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These inhibitors showed good to excellent selectivity over 17-HSD2. The inhibitory activity 
was somewhat reduced in the cell based assay. In general, the inhibitors bearing an aliphatic 
thioether moiety in ring A (compounds 136a-136i) seemed to retain their biological activity 
better. Inhibitor 136b was shown to be a competitive 17-HSD1 inhibitor and to lack 
cytotoxicity in MCF-7 cells. 
 
Some of the potent 17-HSD1 inhibitors, e.g. compounds 136b and 147, also showed good 
inhibition against 17-HSD3 (Table 10),I which is an enzyme converting androstenedione into 
testosterone (Figure 1). However, 17-HSD3 is expressed almost exclusively in male testes and 
thus selectivity between 17-HSD1 and 17-HSD3 isoforms is not an essential feature for an 
inhibitor of 17-HSD1. Nevertheless, these thieno[2,3-d]pyrimidin-4(3H)-one based compounds 
also offer good lead compounds for the development of 17-HSD3 inhibitors, 185 which could be 
used in the treatment of prostate cancer, for example. 
 
In conclusion, several potent and selective 17-HSD1 inhibitors based on a thieno[2,3-
d]pyrimidin-4(3H)-one core were identified in this study. In addition, the compounds did not show 
estrogenic activity in ER or ER receptor binding assay. The most active compounds showed 









The binding mode of thieno[2,3-d]pyrimidin-4(3H)-one based 17-HSD1 inhibitors was 
investigated by molecular modelling. Since previous studies had indicated alternative binding 
modes for substrates,
27
 as well as flexibility of the active site residues,
40
 molecular dynamics 
simulations of 17-HSD1–NADP+–inhibitor complexes were performed,V which could resolve 
the optimal binding mode of the inhibitors. Docking of inhibitors to the active site of a crystal 
structure of 17-HSD1, while informative, does not reveal if an induced fit can be obtained. 
Unlike docking studies with crystal structure complexes, dynamic simulations can mimic the 
physiological conditions.  
 
The lead compound 125 was docked to the active site of a relaxed 17-HSD1–NADP+–E2 
complex and molecular dynamic simulation was performed for the enzyme–cofactor–inhibitor 
complex with the aim of resolving the most plausible binding mode. Subsequently, a set of 
thieno[2,3-d]pyrimidin-4(3H)-one based inhibitors was docked to the representative active site of 
the 17-HSD1–NADP+–125 complex simulation trajectory in order to investigate the structural 
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features contributing to the biological activity of these compounds.
V
 The most potent inhibitor, 
137k, was found to be complementary in structure to the hydrophobic active site, the bulky ring 
D partly extending to the surface of the enzyme (Figure 29).Up to four hydrogen bond 
interactions were formed between 137k and the active site (Figure 30). In the ring A the 
aldehyde group forms hydrogen bonds to Asn152 and Tyr218, the thioether side chain occupies a 
hydrophobic pocket near the catalytic region, and the hydroxy group at the meta position forms a 
hydrogen bond to the backbone carbonyl of Gly144. The pyrimidone carbonyl in the inhibitor 
core forms a hydrogen bond to Arg254, and the thieno[2,3-d]pyrimidone core  is suggested to 
have - interactions with Phe259. In the representative structure of the 17-HSD1–NADP+–125 
complex simulation, the inhibitor 125 (the lead compound), which differs from 137k in the lack 
of phenolic hydroxyl in the thioether side chain, forms two plausible hydrogen bond interactions: 
one between the ring A aldehyde and Tyr218 and another between the pyrimidone carbonyl and 
Arg258. The formation of the two additional hydrogen bonds with 137k is supported by the 
increase observed in the inhibitory activity. 
 
Unexpectedly, docking studies to the relaxed 17-HSD1–NADP+–E2 complex suggested a 
different binding mode for 136b.
V
 Here the cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-one core 
is flipped horizontally relative to 125 (Figure 31). The only difference between 125 and 136b is 
that 136b has an aliphatic thiopropyl side chain in ring A. During subsequent molecular 
dynamics simulation of the 17-HSD1–NADP+–136b complex, 136b was found to turn and shift 
away from the cofactor resulting in longer equilibration time and thus a more unstable complex 
as compared with the 17–HSD1-NADP+–125 complex. This, and the comparable biological 
activity, suggests that 136b could actually bind in similar mode to 125, although docking studies 
indicated otherwise. In the representative 17-HSD1–NADP+–136b complex, only one plausible 
hydrogen bond is observed between the aldehyde group in 136b and Tyr218 (Figure 31). Figure 
32 illustrates the orientation of E2 before and subsequent to the relaxation of the enzyme 
complex, and the orientation of inhibitors 136b and 137k in simulated 17-HSD1-NADP+-
inhibitor complexes.  
 
Finally, with use of the docked conformations and the biological data of 28 selected inhibitors, a 
3D-QSAR model was created to guide further inhibitor development.
V
 The model was validated 
with an external test set, and the correlation (r
2
) between the experimental and predicted 
biological activity for the training set was 0.994. The QSAR model shows good predictive power 











Figure 29. The surface of the active site around NADP
+ 







Figure 30.  The top ranked pose for the most potent inhibitor 137k docked into the active site of 










Figure 31. Representative active site of 17-HSD1–NADP+–136b complex simulation. The dashed line 
indicates plausible hydrogen bond interaction.  NADP
+







Figure 32. The variable positions of the reduced substrate E2 and inhibitors in the active site of 17-
HSD1. E2 (coloured magenta) in the crystal structure of 17-HSD1–NADP+–E2 complex (pdb code 
1FDT) and E2 (coloured blue) after the relaxation of the complex. The most potent inhibitor 137k 
(coloured orange) docked into the active site of simulated 17-HSD1–NADP+–125 complex and 136b 
(coloured green) from 17-HSD1–NADP+–136b complex simulation. The corresponding enzyme 
structures are aligned on the basis on the enzyme backbone. 
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5. CONCLUSIONS  
 
17-HSD1 enzyme is an attractive biological target for the development of inhibitors useful for 
the treatment and prevention breast cancer and other hormone dependent disorders. Several 
potent and selective non-steroidal 17-HSD1 inhibitors without estrogenic activity were 
identified in the study. An efficient synthetic route was developed for the lead compound and 
subsequently utilised in the synthesis of a cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-one based 
molecule library. Around 100 thieno[2,3-d]pyrimidin-4(3H)-one based compounds were 
synthesised, most of which were new chemical entities. 4-(3-Hydroxyphenylthio)-
1,2,7,8,9,10,11,13-octahydro-13-oxo-1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepine-3-
carboxaldehyde 137k is one the most potent 17-HSD1 inhibitors reported to date, with 94% 
inhibition of the recombinant enzyme at 100 nM test concentration. Overall, the establishment of 
novel class of inhibitors is a progressive achievement in 17-HSD1 inhibitor development. 
 
The predictive 3D-QSAR model that was constructed on the basis of this study offers a powerful 
tool for future 17-HSD1 inhibitor development. On the basis of the 3D-QSAR model we can 
now more efficiently utilise structure based drug design in the creation of dicycloalkeno 
thieno[2,3-d]pyrimidin-4(3H)-one based 17-HSD1 inhibitors with good inhibitory potency. 
Future work should also take into consideration the pharmacological properties of thieno[2,3-
d]pyrimidin-4(3H)-one based 17-HSD1 inhibitors, to overcome among other things, the 
relatively poor solubility of some of these compounds. Clarification is also needed of the 
structural factors influencing cell membrane permeability.  
 
The studies on the structure and reactivity of cycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones 
contribute to understanding the chemical reactivity of this compound class. The reactivity of 
dicycloalkeno thieno[2,3-d]pyrimidin-4(3H)-ones towards electrophilic reagents was shown to 
depend on a stereoelectronic effect arising from different ring conformations. In addition, the 
mechanism of the Vilsmeier haloformylation was reviewed and the reaction was shown to 
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